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ABSTRACT
The primary function of the immune system is to seek and eliminate altered or
unhealthy cells. T cells are a significant component of the immune response and
mediate their functions by recognizing specific antigens that eliminate infected or
neoplastic cells. T cells have evolved strategies to discriminate self from non-self or
healthy from altered and infected to avoid inappropriate activation and subsequent
immune injuries. These strategies rely on the activation of receptors that restrict the T
cell response.
CD33rSiglecs are a family of primarily inhibitory receptors that bind to sialic
acids. Siglecs respond to specific sialic acid patterns characteristic for healthy and self
and trigger tolerogenic signaling pathways that prevent activation of the immune
response. To date, the expression of Siglecs in human T cells is not well appreciated.
We found that one Siglec member, Siglec-5, is transiently expressed only on activated T
cells. Using overexpression studies, we showed that Siglec-5 is a potent inhibitor of T
cell activation. The expression pattern, along with the functional studies, suggested that
Siglec-5 is a checkpoint-like receptor that negatively regulates T cell activation. Using a
previously described protein-ligand, we tested if Siglec-5 engagement suppresses the
functionality of human T cells. We found that Siglec-5 reduces the T cells effector
functions, as measured by the production of cytokines and cytolytic molecules.

xvi

Cancers change their sialyation to evade immune recognition, and we
hypothesized that Siglec-5 is a mechanism to enable this. If malignant cells can engage
and activate the Siglec-5 receptor on T cells, they could suppress and evade the antitumor T cell response. Our data demonstrate that soluble Siglec-5 binds to cancer cell
lines from different tissues, suggesting the expression of putative Siglec-5 ligands. We
measured the T cell specific response when the Siglec-5 signaling axis is interrupted
using engineered melanoma-specific T cells. We found that blocking the availability of
Siglec-5 putative ligands on the cancer cells reinvigorates the T cells immune response
against melanoma cancer cells.
Altogether, this work identifies Siglec-5 as a novel checkpoint receptor that
suppresses the activation of T cells. Several checkpoint receptors with similar functions
to Siglec-5 already serve as successful targets for cancer immunotherapies. However,
such therapies work in only a small fraction of cancer patients. Our work shows that
blocking Siglec-5 strongly reinvigorates the T cell response. Alone, or in combination
with other checkpoint targets, blockade of Siglec-5 can serve as a strategy to prevent
cancer immune evasion.

xvii

CHAPTER I: REVIEW OF THE LITERATURE
T Cell Development
The Discovery of the Thymus
T cell development beings in the thymus, an organ that supports the
development and selection of T cells. The thymus was Initially considered a useless
organ; however, in 1960, J. Miller made a bold postulation that “the thymus at birth
may be essential to life”1. Miller provided vital evidence that the thymus is the main
source of immunocompetent lymphocytes during the neonatal period. Using
thymectomized neonatal mice, he showed that skin grafts from up to four different
strains with different coat colors are not rejected1. Based on these studies, he
proposed that key T cell development happens in the thymus during embryogenesis,
from where fully developed lymphocytes migrate to other sites at the time of birth2.
Remarkably, Miller’s studies established that unlike previously thought, thymus
lymphocytes are not immune-incompetent, and instead can respond to antigen
stimulation that can further stimulate bone marrow-derived cells to produce antibodies
3.

Thymic seeding progenitors (TSPs) originate from adult bone marrow and arrive in

the thymus via the thymic cortico-medullary junction. Once in the thymus, progenitor
cells undergo progressive differentiation as they migrate across the morphologically
similar but functionally different regions of the thymus, and before their export into the
periphery 4. It is now apparent that for commitment into the T cell lineage a complex
network of different transcriptional regulators, proliferative and survival signals from

1

2
thymic epithelial cells, and signals from the developing thymocytes, must interplay
into a cooperative activity to support proper development.
Entry of T Cell Progenitors into the Thymus and Early Thymic Development
Upon entry into the thymus, TSPs are defined as CD4-CD8-CD25-CD44hi, or
lineage negative, double negative stage 1 (DN1). At this point TSPs have lost the ability
to enter the erythroid or myeloid lineage, and instead are biased towards the lymphoid
lineage. However, DN1 cells are not yet entirely restricted to the T cell lineage, and can
undertake the B cell, NK cell, or dendritic cell lineage as well5,6. For TSPs to commit to
the T cell lineage, a network of transcriptional proteins is induced and tightly regulates
the process. E-proteins are a subfamily of helix-loop-helix transcription factors that play
an important role during several thymocyte developmental processes. Mice deficient in
E2A gene products have tenfold decrease in thymocyte numbers, as compared to wildtype littermates. As E2A expression is induced when TSPs begin to restrict towards a
potential T cell lineage, the underlying reason for the E2A null mice phenotype is a
developmental defect preceding T cell lineage commitment and initiation of TCR
rearrangemen7,8. Further evidence that supports the role of E2A proteins in T cell
development comes from studies showing that Id proteins, which are negative
regulators of E-protein activity, block T cell and instead favor NK cell lineage
commitment. Altogether, the balance between E- and Id-protein activity is essential in
determining T versus NK cell lineage commitment9,10. Notch is another transcription
factor critical for T cell development and essential for blocking B cell lineage
commitment of TSPs enteringthe thymus. Mice lacking functional Notch1 postnatally
show a defect in thymocyte development presented with a loss of both  or  T

3
lineages, and enrichment in cells carrying all the typical B cell markers11. When TSPs
enter the double negative stage 2 (DN2), defined as CD4-CD8-CD25+CD44hi, they have
already lost the ability to become NK or B cells but can still become T cells or dendritic
cells12. During this stage, developing cells begin T cell receptor (TCR)-, TCR-, and
TCR- gene rearrangement, The rearrangement of the TCR chains is a process
mediated by RAG1 and RAG2, and drives TSPs towards total commitment to the T cell
lineage13–15. However, at this stage, cell proliferation is arrested and requires the
formation of the pre-TCR complex for cell growth to continue. Thus, when entering the
double negative stage 3 (DN3), defined as CD4-CD8-CD25+CD44lo, cells that have
successfully rearranged their TCR- chain now pair up with an invariant, germlineencoded pre-TCR- and CD3 to form the pre-TCR. Pre-TCR signaling leads to forcing
the -chain selection, rescuing cells from apoptosis, supporting further cell proliferation,
and silencing the TCR- rearrangement16–19. The selection of the -chain mediates loss
of CD25, which leads to the final stage of the lymphopoiesis, double negative stage 4
(DN4), a transient state that is also considered as the pre-double positive (DP) stage.
Pre-TCR signaling is also essential for initiating the TCR- rearrangement, which is
completed in the DP stage. If TCR- successfully rearranges at the double positive
CD4+CD8+ state, thymocytes will express -TCR, allowing for positive and negative
selection and differentiation into single positive CD4 + helper, or CD8+ killer lineage20,21.
Alternatively, if the developing thymocytes successfully rearrange both their TCR- and
TCR- loci, they will express a -TCR. Expression of -TCR also initiates a burst in
proliferation, however, these cells avoid entering the DP stage of development and
instead enter the periphery as CD4-CD8- cells. Interestingly, it is suggested that the

4
TCR type,  or  is not what determines the lineage fate of the T cells; instead, it is
the strength of the TCR signal that makes a choice. Compared to the pre-TCR,
composed of a rearranged  and invariant  chain, the -TCR induces stronger TCR
signaling events (high levels of phosphorylated Erk and strong induction of Egr family of
transcription factors) which favor the -T cell lineage. However, manipulations
designed to reduce the strength of -TCR signaling by altering the surface levels of TCR, the amount of signaling molecules, or the removal of the -TCR ligands, favor the
-TCR lineage cells22–24. Yet other studies suggest a pre-commitment model, where
the lineage choice is made prior to TCR expression 25,26. The reconciliation between the
two models has been that the TCR signal strength is essential to confirm the precommitment choice for lineage differentiation. In the case that the two are incompatible,
the cell gets eliminated.
Positive and Negative Selection
Upon -chain rearrangement, and as soon as pre-TCR signaling begins in DN
precursor cells, gene rearrangement of the -chain is initiated. Even though low levels
of -chain rearrangement can be detected during the final DN4 stage of development,
active and efficient rearrangement occurs once the cells become quiescent DP.
Nevertheless, rearrangement of the -chain does not stop until the TCRs successfully
engage with a major histocompatibility complex (MHC) peptide during positive selection.
In other words, surface expression of an -TCR does not reduce the activity of RAG1
and RAG2, and thus -chain rearrangement continues. It is postulated that the
developing T cell uses these events to try different combinations of -TCRs to choose
only those that successfully bind to MHC peptides (pMHC)27,28. DP thymocytes that
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interact poorly with MHC-peptide complexes and thus don’t receive the intracellular
threshold signaling required for survival, die by a process known as death by neglect.
Conversely, a small fraction of the DP thymocytes has a strong affinity for the MHCpeptide. If permitted to egress in the periphery, these cells could cause autoimmune
related pathologies. Intracellular signaling triggered by strong affinity interactions results
in rapid apoptotic death, also termed negative selection. Thus, only cells with
intermediate affinity for MHC-peptide are permitted to survive and differentiate into
single positive (SP), CD4+CD8- or CD4-CD8+, T cells29,30. But how does the TCR-pMHC
interaction determine whether a DP thymocyte will become CD4 + or CD8+? A critical
step in positively selecting a DP thymocyte is the quality of the interaction between the
TCR and pMHC. TCR and pMHC interactions dictate the proximal signaling events that
will be triggered in that T cell, and the pairing of either CD4 or CD8 co-receptors plays a
crucial role in the quality of that signal. The lineage commitment only occurs when TCRpMHC class I engage with CD8, and TCR-pMHC II engage with CD4 co-receptor. In
fact, the strength of the signal generated when CD4 or CD8 engage with the appropriate
TCR-pMHC complex makes the decision, with prolonged signals leading to CD4 + and
short signals leading to CD8+ T cells. Molecularly, the CD4 and CD8 co-receptors bind
to the TCR-pMHC complex and stabilize the receptor-ligand interaction, thus decrease
the dissociation rate between the TCR and pMHC. Furthermore, the co-receptors also
increase the strength of the signal as they can directly bind and recruit Lck to the
immunological synapse31–33. Lck is a cytoplasmic kinase which activity dictates the
duration and strength of the downstream signaling cascade, and thus the fate of the
developing thymocyte34–37. CD4 associates with Lck more efficiently and thus brings
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more Lck to the TCR complex for signaling. Subsequently, when CD4 engages with the
right TCR-pMHC complex the developing thymocyte receives a stronger signal that
drives the cell into a CD4 lineage38,39. The efficiency of positive selection is highly
dependent on the thymic microenvironment and the thymic cortical epithelial cells
(cTEC). Unlike other epithelial cells, cTECs possess a unique protein degradation
machinery, the thymoproteasome, which generates the pool of ligands necessary to
select for vast TCR pool that reacts to foreign, but not self-antigens. Crosstalk between
the developing thymocytes and the cTEC is an essential component in the process of
positive selection, as DN thymocytes generate the signals for the development of
cTECs40.
Completion of Thymocyte Development
Regardless of the strength of the TCR signal, when developing thymocytes
receive TCR stimulation, they upregulate CCR7. This chemokine receptor allows their
migration from the cortical to the medullary region of the thymus, where CCR7 ligands
(CCL19 and CCL21) are expressed. However, since negatively selected T cells are
destined to die, only positively selected T cells to migrate. Crosstalk between the
developing thymocytes and the medulla is essential for the cells to migrate, as
successful positive selection is required for formation of the architecture of the
medulla41,42. When SP T cells arrive in the medulla, they are functionally incompetent,
and susceptible to apoptotic signals, and need to undergo maturation processes before
being sent into the periphery43. Furthermore, the maturation processes are also
accompanied by a second round of selection and deletion of tissue-reactive thymocytes
that have escaped cortical negative selection. Negative selection in the medulla is
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mediated in part by the activity of the transcription factor autoimmune regulator element
(AIRE), and the presentation of peripheral tissue-specific peptides by medullary TECs44–
47.

Additionally, the medulla is where natural regulatory T cells (Tregs) are generated as

well. A specialized structure within the medulla, known as the Hassal’s Corpuscle, plays
a vital role in the generation of Tregs via production of the cytokine thymic stromal
lymphopoietin (TSLP). TSLP activates medullary dendritic cells that drive the induction
of Foxp3+ regulatory T cells. Altogether, the medulla is essential for central tolerance,
as it ensures deletion of auto-reactive T cells while also producing regulatory T cells
specific for peripheral self-antigens48–50.
Export of Mature T cells into Circulation
When thymocytes reach the mature state, they begin expressing high levels of
the sphingosine-1-phosphate receptor 1 (S1P1), a G-protein coupled receptor. The
ligand for S1P1, S1P, is highly expressed in serum, and not so much in tissues, and
thus acts as a chemoattractant that drives mature thymocytes to egress from the
thymus and into the perivascular space, which channels into the post-capillary venules,
arterioles, and lymphatics51,52.
Naïve T cells
Upon positive and negative selection in the thymus, mature thymocytes egress
into the periphery as naïve or antigen inexperienced T cells. However, with age, the
thymus regresses, loses its tissue organization, and thus results in less efficient T cell
development and reduced naïve T cell output53,54. As the ability of the adaptive immune
system to mediate adequate immune responses against foreign antigens depends
mainly on the TCR diversity generated during thymopoiesis, a functional pool of naïve T
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cells must be maintained throughout an individual lifetime. Interestingly, unlike mouse
naïve T cells, which derive from continuous thymic output throughout life, human naïve
T cells derive from continuous peripheral T cell division and can persist for 5-10
years55,56. Thus, besides loss in thymic output and a decline in the overall frequency,
human naïve T cells preserve their diversity and functionality even at old age through
peripheral post-thymic expansion57,58.
Recent Thymic Emigrants
Naïve T cells that have just egressed from the thymus are also called recent
thymic emigrants (RTEs). Phenotypically, RTEs are characterized by the expression
of IL7RαloTCRhiCD3hiCD28loCD24hiQa2loCD45RBlo, as well as the protein tyrosine
kinase 7 (PTK7) and CD31 for CD4 and CD103 for CD8. RTEs are functionally different
than mature naïve T cells as they manifest reduced proliferation and cytokine
production in response to TCR/CD3 and CD28 stimuli. In fact, the functional differences
are reflected by the different epigenetic states, with RTEs naïve T cells having
hypermethylated promoters for the Il2 and Il4 genes, compared to both the precursors
of RTEs and mature naïve T cells59. Furthermore, RTEs also have a much more
diverse TCR repertoire compared to mature naïve T cells60,61. Altogether, RTEs are a
transitional but important T cell compartment in which functional responses are tightly
regulated.
Naïve T cell Maturation
In order to enter the fully functional, long-lived mature naïve T cells state, RTEs
must undergo a T cell maturation process that occurs specifically in secondary lymphoid
organs (SLOs)62. Compared to RTEs, mature naïve T cells have a less diverse TCR
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repertoire, suggesting that TCR-pMHC interactions in the SLOs might lead to the
deletion of certain RTE clones. Even though the details of RTE maturation are precise,
it is known that the process is independent of TCR signaling, even though TCR
engagement is required for shaping the TCR repertoire of mature naïve T cells63,64.
A transcriptional repressor, NKAP, is involved in the maturation process, as T
cells lacking NKAP remain stuck at the RTE stage. However it is unclear how NKAP
mediates its effects65. An explanation for the requirement of extra-thymic naïve T cell
maturation could be that it provides another checkpoint to ensure self-tolerance. Even
though central tolerance mechanisms (i.e., negative selection) in the thymus are highly
efficient processes, self-reactive T cells, especially ones with lower affinity for selfantigens, manage to egress to the periphery.
Within SLOs, extrathymic Aire-expressing cells present self-antigens and are
capable of deleting of self-reacting cells66; since RTEs require entry in the SLOs in order
to transition to mature naïve T cells, it could be that self-reacting RTEs are also deleted
before becoming mature naïve T cells. The fact that the TCR repertoire of mature naïve
T cells is much less diverse compared to RTEs could also serve as circumstantial
evidence that RTEs clones that react to self-antigens within the SLOs are eliminated.
T cell Subsets
When naïve CD4+ and CD8+ T cells encounter their cognate antigen, in the
context of MHCII and MHCI, respectively, they differentiate into various cellular subsets,
helper or regulatory, for CD4+, or cytotoxic or regulatory, for CD8+. Besides the TCR
stimuli67, efficient and appropriate activation and differentiation also require two
additional signals, one coming from co-stimulatory molecules, most often CD28, which
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amplify or modify the signaling cascade initiated by the TCR 68,69, and the other from
cytokines in the environment, which skew the signaling cascades toward polarization of
the cells into different subsets70.
CD4+ T cells
CD4+ T cells, or helper T cells, play a central role in mediating adequate immune
responses via direct or indirect involvement. Not only do helper T cells respond
themselves to antigens, but they also provide critical help in the production of antibodies
by B cells, the cytolytic activity of CD8 T cell, and the activity of various innate immune
cells. The diverse functions that helper cells can perform are enabled by the
differentiation of naïve CD4+ T cells into specific subsets upon stimulation with their
cognate antigen. While antigen concentration or different co-stimulation molecules can
influence the helper subset that naïve CD4 can become, the critical regulators in the
process are the different cytokines present in the milieu.
In the late 80s, Mossman and Coffman first reported two T helper subsets, Th1
and Th2, each producing distinct set of cytokines, and thus shaping the immune
response in a different direction71,72.
Th1. The critical cytokines that drive Th1 differentiation are interleukin-12 (IL12)73 and interferon- (IFN-)74, which synergize into a signaling cascade that leads to
the expression of the Th1 master transcription factor, T-box expressed in T cells (Tbet)75. The signature cytokine for Th1 cells is IFN-, but they also produce IL-2 and
tumor necrosis factor- (TNF-). Using cytokine-mediated mechanisms, Th1 cells
direct cell-mediated immune responses to ensure eradication of intracellular pathogens,
but also mediate autoimmune tissue inflammation.
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Th2. On the other hand, IL-4 plays a central role in the differentiation of the Th2
helper subset. IL4 triggers a STAT6 dependent signaling cascade that upregulates
expression of the transcription factor GATA376,77. GATA 3 is the master regulator of the
Th2 cell lineage and potentiates the cells into producing more IL-4 and other cytokines,
such as IL-5, IL-9, and IL-1378,79. Via the cytokines they produce, Th2 cells orchestrate
immune responses that target helminth infections and facilitate repair of damaged
tissues and contribute to chronic inflammatory diseases such as asthma and allergies.
Th17. In 2005, a third, distinct lineage of CD4 T-cells, known as Th17, was
reported80,81. The key cytokines for Th17 differentiation are a combination of
transforming growth factor- (TGF-) and IL-6, with TNF- and IL-1 further enhancing
the differentiation process82–85. The signature cytokine of Th17 cells is IL-17A
(commonly known as IL-17), but they also produce IL-17F, TNF-, IL-21, IL-22, and IL26. The master regulator of Th17 cell differentiation is the orphan nuclear receptor
ROR-t, which regulates the transcription of IL-17 and the related cytokines86. Th17
responses are critical in mediating mucosal immune responses against both intracellular
and extracellular bacteria and some fungi. However, the Th17 subset is also the primary
mediator of several autoimmune diseases such as rheumatoid arthritis, psoriasis,
Chron’s disease, etc.
Tregs. The existence of multiple CD4+ helper subsets can be explained by the
unique programs triggered by each subset in orchestrating the immune response.
However, an inappropriate or overly active immune response can often enable the
development of immune pathologies and autoimmune disorders. Such improper
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responses are often initiated against self-antigens, innocuous antigens found in food,
and commensal bacteria or fetal antigens.
A critical CD4+ T cell subset, known as regulatory T cells, is dedicated to
constraining the expansion and activity of such pathogenic T cells. The idea for the
existence of suppressive T cells dates back to the late 60s87; however, it was not until
1995 when strong evidence was provided that T cells can induce immune tolerance. In
a seminal paper, Sakaguchi et al. described a unique CD4+ T cell subset, defined by
the constitutive expression of CD25, the IL-2 receptor -chain, that is responsible for
down-regulating immune responses against self- and non-self antigens88. It was later
elaborated that Tregs can be generated in two ways: 1) in the thymus, during negative
selection (naturally arising regulatory T cells) and 2) in the periphery by co-stimulation of
naïve T cells with antigen, TGF- and IL-2 (peripheral Tregs)89. The master regulator for
the development and function of both thymic and peripheral regulatory T cells is the
forkhead transcription factor Foxp3, which maintenance is dependent on TGF-90,91.
Another cell subset involved in mediating immune tolerance against self-antigens
is the type 1 regulatory T cells (Tr1). Tr1 cells are generated by chronic antigen
stimulation in the presence of IL-10. Tr1 lacks expression of Foxp3 but constitutively
produces high levels of IL-10 and low levels TGF- and thus suppresses pathological
immune responses92.
Th9 and Th22. In vitro studies suggest that little to no plasticity occurs between
Th1 and Th2 subsets, with cells fixating on a specific lineage shortly after stimulation.
However, it has been suggested that plasticity might occur between effector programs
that are more closely related. Such examples are the Th9 and Th22 cell lineage. Th9
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cells are characterized by IL-9 expression, and so far, lineage-specific transcription
factors have not been described. These cells develop when naïve helper T cells are
activated in the presence of both IL-4, a Th2 inducing cytokine, and TGF-, a driver for
Tregs and Th17 lineages. It is postulated that in this setting, TGF- acts as a regulatory
“switch” whereby in combination with IL-4 changes the fate of the developing cells from
the Th2 into the Th9 lineage93,94. Th9 cells are implicated to contribute to anticancer
immunity, with IL-9 mediating activation of dendritic cells, mast cells, natural killer cells,
and CD8 T cells95,96.
Similarly, it is not clear whether Th22 cells are a separate lineage, or a derivative
of the Th17 cells as they both share the production of the cytokine IL-22. The immune
contribution of Th22 cells is not well defined, and it is primarily thought that the function
of their main cytokine, IL-22, is context-dependent. For example, in the presence of IL17, IL-22 plays a proinflammatory role, whereas in the absence of IL-17, it is tissue
protective97–99.
CD8+ T cells
Upon encountering an antigen in the context of MHC I, naïve CD8 T cells
differentiation into effector cytotoxic T lymphocytes (CTLs). Naïve CD8 T cells are
developmentally pre-programed for clonal expansion and differentiation, and thus upon
a brief period of antigen stimulation (2-24hrs) they undergo rapid and robust
expansion100–102. CTLs are equipped with specialized cytotoxic mechanisms, such as
cytokine production and cytolysis to eliminate infected or unhealthy cells. However,
effector CTLs are not long-lived; instead, after clonal expansion peaks, effector CTLs
enter a contraction phase. During the contraction phase, 90-95% of the cells die via
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apoptosis; the remaining 5-10% of effector cells survive as long-lived memory cells.
This memory population is of great importance as they can rapidly mobilize their effector
mechanisms in response to re-encounter of the cognate antigen103,104.
T Cell Receptor Signaling
Antigen Recognition
T cells possess clonal identity due to the unique TCRs generated because of
genomic DNA rearrangement during development in the thymus. Therefore, naïve T
cells use their TCRs as antigen detectors to survey antigenic peptides, complexed with
MHC I or II (pMHC), that are novel or have never been experienced before. Initially, it
was thought that efficient immune response against foreign antigens was due to the
massive number of TCRs, where one clonotype is specific for a single antigenic
peptide105. This view, based on the clonal selection theory106, was later abandoned, as it
was shown that T cell clones can recognize and respond to alternative peptide/MHC
ligands that were significantly different from the cognate antigen that the clones were
selected for107,108.
The human naïve T cell pool is estimated to have <10 8 distinct TCRs109, while the
estimated pool of antigenic peptides is >1015, based on the 20 amino acids available110.
Since the number of potential antigens exceeds the number of available TCRs, an
effective immune response is only possible if each TCR recognizes more than one
peptide. The reactivity of T cells is regulated by their antigen sensitivity, a measure for
the activation threshold in response to an antigen. Antigen sensitivity is greatly affected
by the TCR affinity for the peptide, the expression levels of the TCR on the cells, and
the expression of co-stimulation molecules. Additionally, the co-receptors CD4 and CD8
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play a direct role in modulating the T cell response against antigens. In the case of
helper T cells, CD4 augments T cell activation mainly by bringing Lck to the TCR
signaling complex, but some effects also come from CD4 binding to the TCR-pMHC
complex38,39. On the other hand, CD8 augments the CTL response by reducing the “off”
and enhancing the “on” rate of TCR-pMHC engagement111–113. Altogether, even though
one TCR can cross-react with multiple antigens, the threshold for activation is affected
by several parameters that ensure a proper immune response.
Initiation of TCR Signaling
When the TCR engages with a pMHC, the mechanical information is translated
into a chemical reaction by recruiting the Src family kinase Lck to the TCR complex. Lck
phosphorylates tyrosine residues within the ITAM of the CD3 zeta chain, which serve as
docking sites for the SH2 domains of the Zap70 kinase. Once at the plasma membrane,
the autoinhibition of Zap70 is relieved by Lck mediated phosphorylation, and Zap70 can
trigger the downstream signaling cascade114. How engagement of TCR with pMHC
triggers the TCR signaling cascade, or how the TCR distinguishes engagements of
different affinity are not well understood, but several different models are proposed.
According to the “kinetic proofreading” model, engagement of a TCR to pMHC is
translated into a signal only if the TCR complex is phosphorylated before dissociation
occurs. In other words, discrimination between antigens is based on the on- and offrates or the duration of the TCR-pMHC interaction, with low affinity or non-specific
interactions failing to elicit a response because dissociation occurs faster than signal
generation115–117. The ‘co-receptor scanning’ model extends the “kinetic proofreading”
model and suggests that the kinetics of co-receptor mediated delivery of Lck to the TCR
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complex is the rate-limiting step that allows for kinetic proofreading to occur. As coreceptors CD4 and CD8 bind to Lck via their cytoplasmic tail, they recruit Lck to the
TCR complex, triggering the TCR signaling cascade118. However, only a minority of
CD4 and CD8 are bound to catalytically active Lck (2% and 0.2% respectively). Thus
the “co-receptor scanning” model proposes that in the duration when a TCR is bound to
a pMHC, the complex scans several hundreds of co-receptors until it finds an Lckloaded one. The “co-receptor scanning” model proposes a mechanism for initiation of
TCR signaling where the weak agonists, which have shorter half-times of pMHC-TCR
interaction, have less time to recruit Lck loaded co-receptors and thus fail to elicit a
response119. This model is supported by the fact that increased availability of active Lck
enhances TCR responsiveness to low affinity pMHC, further suggesting that Lck might
be the first necessary step in triggering of response120.
However, in vivo resting T cells have a fraction of Zap70 already bound to
phosphorylated ITAM  chains, although these Zap70 molecules require Lck mediated
activation121. So a modification for the “co-receptor scanning” model is proposed,
whereby basal levels of active Lck allow continuous ITAM phosphorylation and Zap70
recruitment. Instead, the rate limiting step for activation of the TCR signaling cascade is
Lck mediated activation of Zap70, which is only triggered upon longer-lived TCR-pMHC
interactions122. Another model, “kinetic segregation” suggests that Lck randomly
encounters and phosphorylates the TCR complex. Still, phosphatases, such as CD45
which continuously counteract the Lck activity, keep the net phosphorylation of the TCR
 chain at low levels. However, when a T cell encounters an APC, close-contact zones
are formed, where the TCR and other proteins bind to their ligands, while large
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molecules are excluded due to their steric hindrance effects123. According to the “kinetic
segregation” model, as TCR-pMHC interaction leads to the formation of an
immunological synapse where bulky molecules, such as CD45, are excluded, the
balance between Lck and CD45 is disrupted and now T cell activation can proceed as
net phosphorylated TCRs increase124–126. Other models suggest that the mechanical
forces exerted upon TCR-pMHC interaction trigger and potentiate the TCR signaling
cascade. Many proteins undergo conformational changes, which trigger their active
state; interestingly, this is not the case for the TCR. Upon TCR-pMHC interactions,
noticeable conformational changes only occur within the TCR CDR loops, which interact
with the pMHC. However, besides no conformational changes in the distal parts of the
TCR, mechanical forces do trigger TCR signaling 127,128, and evidence for a
mechanosensitive mechanism of TCR activation has been reported. When the TCRCD3 complex assembles, the juxtamembrane (JM) region of the  are forced apart
from what is proposed to be an “off” conformation; TCR engagement reorients the 
JM regions so that they move together into an “on” conformation. These pivot points at
the linkage between the TCR and  JM regions are thought to translate the
mechanical force of TCR-pMHC engagement into a sequence of biochemical events
that lead to T cell activation129,130. Because all models discussed are based on
experimental observations, it is likely that all or some together can be applied to explain
how TCR signaling is initiated.
Proximal TCR Signaling
Because the TCR lacks enzymatic activity, it requires the activities of the tyrosine
kinases Lck and Zap70 which turn the extracellular recognition of an antigen into a
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biochemical signaling cascade that culminates into T cell activation, proliferation, and
differentiation. Lck is a Src family kinase (SFK), and its activity is mainly controlled by a
balance between phosphorylation and de-phosphorylation of the inhibitory, Y505, and
activating, Y394, residues. Structurally, Lck comprises of Src homology (SH) 2, SH3,
kinase domain and an N-terminal cysteine rich motif that allows its association with the
co-receptors CD4 and CD8131. The C-terminal Src kinase, Csk, phosphorylates Lck on
the C-terminal end at Y505 and creates a docking site for the SH2 domain. In this form,
Lck is in a closed, or autoinhibited conformation, which is further stabilized by the SH3
domain binding to a polyproline helix region in the linker region132–134. Csk activity is
counteracted by the plasma-membrane localized tyrosine phosphatase CD45, which
dephosphorylates Y505 and generates a pool of Lck in the open or primed
conformation135–137. Autophosphorylation at Y394 allows for Lck activation and
downstream substrate phosphorylation138. A pre-existing pool of already active Lck is
thought to exist at all times119,139, but de novo activation, mediated by T cell activation,
contributes as well140. On the other hand, TCR-pMHC interaction is required for Lckmediated phosphorylation of ITAMs within TCR-associated CD3 and  chains.
Phosphorylation of both tyrosine residues in the ITAM creates docking sites for the SH2
domain of Zap70. Zap70 is thought to be in an autoinhibited, close conformation in the
cytoplasm, and its recruitment to the TCR complex partially relieves that autoinhibition.
Lck phosphorylates Zap70 at Y315, Y319, and Y493 which entirely relieves its
autoinhibition by promoting an open conformation and full catalytic activation141. To
sustain its localization to the TCR complex, and enhance the catalytic activity of both
kinases, the SH2 domain of Lck binds p-Y319 of Zap70, an interaction critical for T cell
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activation122,142. Downstream of Lck and Zap70 are the adaptor molecules LAT (the
linker for activation of T cells) and SLP-76. LAT and SLP-76 play a critical role in
mediating TCR signaling as they serve as nucleating sites for multi-protein complex
formation, essential for T cell activation143,144. Zap70 phosphorylates LAT and SLP-76 at
multiple tyrosine residues, which serve as docking sites for recruitment of downstream
signaling molecules essential to trigger signals such as calcium mobilization and MAPK
(mitogen-activated protein kinase) activation145. Considering that to be fully activated,
Zap70 localizes at the cytoplasmic portion of the TCR complex,and that Zap70 and LAT
for example are spatially segregated, it is not understood how LAT phosphorylation is
maintained during T cell activation. One possible mechanism is by “catch-and-release”
which suggests a cycle of recruitment, activation, and dissociation of Zap70 upon TCR
stimulation. The dissociated, but active Zap70 diffuses within the plane of the plasma
membrane to sites where it can encounter and phosphorylate its substrates, i.e., LAT.
The TCR signal is then amplified as the unoccupied sites of the TCR become available
for activation of additional Zap70 molecules that go through the same cycle 146. A caveat
for this proposed mechanism is that it can uncouple the TCR signaling cascade and
cause a premature end of Zap70 kinase activity via phosphatases or ubiquitin
ligases147,148. Another model favors the idea of active recruitment of LAT to Zap70,
where Lck serves as a molecular bridge. Based on this model, Lck binds to Zap70 using
its SH2 domain and binds a conserved proline-rich motif in LAT via its SH3 domain,
thus enhancing Zap70 mediated phosphorylation of LAT149. LAT phosphorylation is
thought to serve as a critical kinetic bottleneck in the propagation of TCR signaling. In
fact, among the several tyrosine residues, Y132 is suggested to play the unique role of
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discriminating between different ligands and strengths of TCR activation150. LAP Y132 is
of great importance because it recruits PLC- 1 and mediates its activation by the Tec
family kinase Itk151. Activation of PLC- 1 leads to calcium mobilization and MAPK
activation, and eventually T cell response. What makes LAT Y132 so critical in
regulating T cell activation is a glycine residue at the G131 position. Zap70 strongly
favors tyrosine residues preceded by an acidic residue, such as Aspartic or Glutamic
acids, and thus G131 in LAT makes Y132 a poor substrate. G131 slows down
phosphorylation of Y132 by Zap70 which perhaps serves as a mechanism for the T cell
to discriminate between different signal strengths and appropriately activate PLC-1 and
the events downstream of it150.
Distal TCR Signaling
Proximal TCR signaling culminates in the activation of PLC- 1, an event critical
for T cell activation. The two events are bridged together via the adaptor molecule linker
for activation of T cells (LAT). LAT is a transmembrane protein that localizes to
membrane lipid rafts via posttranslational modifications, and as a substrate of Zap70
links TCR-pMHC engagement to T cell activation152. Upon phosphorylation at multiple
tyrosine residues, LAT serves as a nucleating site for recruitment of downstream SH-2
containing signaling molecules, notably Grb2, Gads and PLC- 1. Via the intermediate
linker Gads, LAT associates with the src homology (SH)2 domain-containing leukocyte
phosphoprotein of 76 kDa (SLP-76), and together promote downstream TCR signaling
by creating a platform for membrane localization and subsequent activation of PLC1153–155. Following activation, PLC- 1 hydrolyzes phosphatidylinositol 4,5bisphosphate (PIP2) and generates the second messengers inositol 1,4,5-triphosphate
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(IP3) and Diacylglycerol (DAG)156,157. IP3 and DAG simultaneously activate several
signaling pathways, which lead to the activation of transcription factors critical for the
induction of T cell activation-related genes. These transcription factors are: Nuclear
factor for activated T cells (NF-AT), NF-kB and activator protein-1 (AP-1).
DAG-mediated Signaling Pathways
DAG is a lipid second messenger which in T cells binds to conserved domain 1
(C1) containing proteins158, such as protein kinase C (PKC)  and Ras guanyl
nucleotide releasing protein (RasGRP1). In response to increased DAG levels, both
PCK and RasGRP1 translocate to the internal membranes159,160, triggering signaling
pathways critical for T cell activation. RasGRP1 is a guanidine exchange factor (GEF)
that links TCR activation to the MAPK signaling pathway by activating the small GTPase
protein Ras161,162. Even though RasGRP1 plays a dominant role, Ras can also be
activated by a second GEF, SOS, which gets recruited to the LAT signaling complex via
the adaptor molecule Grb2. Ras triggers the MAPK signaling pathway by sequential
activation of Raf-1, a MAPKKK, which then activates MEK, a MAPKK, which in turn
activates the MAPK’s extracellular signal-regulated kinase 1 (Erk1) and Erk2. Erk
activates the transcription factor Elk-1, which regulates Fos expression and thus
contributes to the activity of the AP-1 TF, a complex of Jun/Fos proteins. PKC-
regulates the assembly of the Carma1, Bcl10, and MALT1 (CBM) complex which acts
as a signalosome and regulates the activation of NFkB. Upon initiation of TCR
signaling, Carma1, and PKC- are recruited to the plasma membrane, where PKC-
phosphorylates Carma1 and releases it from the autoinhibited state. Activated Carma1
induces the assembly of the CBM complex as it recruits Blc10 and MALT1. Even though
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the detailed process is not well understood, it is thought that the CBM links to NFkB
activation via activation of IkB kinase (IKK) which phosphorylates and targets for
degradation of the IkB proteins. Degradation of IkB releases NFkB allowing for their
translocation to the nucleus. Besides CBM signalosome mediated activation, NFkB can
also be activated by the Akt signaling pathway as well 163,164.
Calcium-dependent Signaling Pathways
PLC-1 generated IP3 unleashes calcium mobilization following T cell activation.
IP3 binds to IP3R on the endoplasmic reticulum (ER) which stimulates Ca 2+ release
from the ER to the cytoplasm. Depleting ER Ca2+ stores activate Ca2+ release activated
Ca2+ (CRAC) channels on the plasma membrane, leading to further influx of Ca2+ into
the cell cytoplasm. Intracellular Ca2+ binds to a small calcium-binding protein,
calmodulin. Calmodulin regulates the calmodulin-dependent phosphatase, calcineurin,
which in turn de-phosphorylates members of the NFAT family of proteins. Efficient dephosphorylation of NFAT uncovers a nuclear localization signal that enables NFAT
translocation from the cytosol into the nucleus. In the nucleus, NFAT proteins complex
with other transcriptional regulators activated in response to TCR, co-stimulation or
cytokine signaling. For example, the interaction of NFAT and AP-1, a Ras pathway
regulated TF, leads to gene programs necessary for T cell activation and IL-2
production. In contrast, in the absence of AP-1 NFAT complexes with other proteins and
can mediate anergic T cell programs165,166.
T cell Co-signaling
Co-signaling receptors, including co-stimulatory and co-inhibitory, play a pivotal
role in regulating T cell activation. The discovery of the proto-type co-stimulatory
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receptor CD2869 provided evidence for a two-signal model of T cell activation where
functional T cells are generated only in the presence of both TCR and co-stimulatory
signals. In contrast, lack of co-stimulation generates anergic or unresponsive T cells167.
While TCR signaling is required to initiate the immune response, co-signaling is
required to optimize and direct the outcome of the immune response. Because cosignaling can either be co-stimulatory and synergize with TCR signaling or co-inhibitory
and antagonizes TCR signaling, tight spatiotemporal regulations exist, with receptor cell
surface expression being the primary mode of regulation and differential patterns of
receptor-ligand expression being the secondary mode of regulation. To understand the
fluidic expression of co-signaling receptors, especially the dynamics between costimulatory and co-inhibitory receptors, the concept of the tidal model is proposed168.
Based on this model, T cell activation is compared to an incoming tide where costimulatory receptors synergize with TCR signaling and drive the resting T cell towards
a functional state. At peak tide, opposing molecular forces represented by a fine
balance between co-expression of co-stimulatory and co-inhibitory receptors pull the T
cell into distinct functional responsiveness. As the tide regresses, co-stimulatory
receptors are replaced by co-inhibitory receptors, which antagonize TCR signaling and
suppress the T cell activation168. Altogether, co-signaling receptors play a crucial role in
fine-tuning the fate of T cells through regulation of the activation, differentiation, and
proliferation of the T cells.
Co-stimulatory Receptors
CD28. CD28 is the prototype and most efficient co-stimulatory receptor required
to initiate productive T cell activation upon engagement of the TCR 169,170. Lack of CD28
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signaling during T cell activation leads to T cell apoptosis or anergy, where T cells
cannot proliferate or produce cytokines171. Unlike other co-stimulatory receptors, CD28
is constitutively expressed on ~80% of human T cells (~95% of CD4 and ~50% of CD8
T cells) and ~100% of mouse T cells172. CD28 engagement triggers a distinct signaling
cascade than TCR69. However, CD28 signaling synergizes and augments the TCR
signaling cascade and eventually leads to cytokine production, most significantly IL-2173,
because of increased transcription and stability of mRNA174. Furthermore, CD28
signaling leads to increased expression of the anti-apoptotic protein BCL-XL, a member
of the BCL-2 family, and thus promotes the survival of T cells175,176. CD28 signaling is
thought to increase the sensitivity of T cells to respond to even suboptimal
concentrations of antigen. In fact, one study suggests that for a T cell to initiate an
antigen-specific response, a threshold of ~8000 TCRs has to be reached, whereas a
threshold of ~1500 TCRs needs to be reached in the presence of CD28 costimulation177. To initiate the co-stimulatory signal transduction, CD28 uses an MYPPPY
motif within the extracellular domain for binding to its ligand proteins, B7-1 (CD80) and
B7-2 (CD86) expressed mainly on professional antigen-presenting cells178–180. CD28
mediates signaling through its short cytoplasmic tail, which lacks an enzymatic function
but has several conserved motifs that serve as sites for recruitment of other proteins or
sites for modifications that subsequently relay the signaling cascade181. However, even
though CD28 is considered as the primary co-stimulatory receptor for T cell activation,
CD28 alone is not enough to sustain a prolonged T cell response. Instead, the
existence of alternative co-stimulatory pathways is required to further amplify and
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sustain an effective T cell response and/or drive the development of memory T cell
subsets182.
ICOS. The inducible co-stimulatory molecule (ICOS) is a member of the CD28
family of receptors. Similarly to CD28, ICOS can greatly enhance the activation,
proliferation, and effector functions of T cells in response to antigens. Unlike CD28
which is constitutively expressed on almost all T cells, ICOS expression is detected only
in activated and memory T cells183. ICOS ligand (ICOSL) expression is mainly restricted
to professional antigen-presenting cells, such as B cells184,185, dendritic cells, and
macrophages186,187, but certain endothelial188 and lung epithelial cells189 can express it
too. The most striking defect of ICOS deficient T cells is a failure to produce IL-4, a
hallmark Th2 cytokine. Furthermore, ICOS or ICOSL knock-out mice fail to elicit a
humoral immune response against various antigens. These data stress the importance
of ICOS in allowing T cells to provide help in antibody production against foreign
antigens. However, ICOS deficient mice are also more susceptible to the development
of autoimmune inflammatory diseases, such as experimental autoimmune
encephalomyelitis (EAE). Altogether, ICOS is a crucial co-stimulatory receptor that
drives T cells toward induction of a humoral over inflammatory autoimmune
response190. Even though ICOS and CD28 have a similar cytoplasmic tail, and mediate
partially overlapping signaling cascades, key differences, especially in the PI3K and
MAPK signaling, make the functional outcomes of these two co-stimulatory receptors
different191.
4-1BB. 4-1BB (CD137) is an inducible co-stimulatory receptor from the tumor
necrosis factor receptor super family (TNFRSF) expressed in response to T cell
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activation192. 4-1BB can also be expressed on NK cells, B cells, macrophages,
monocytes, dendritic cells, and granulocytes193. Like other co-stimulatory molecules,
activation of 4-1BB signaling results in robust proliferation, cytokine production and
survival of T cells194 4-1BB is activated by 4-1BB-ligand (4-1BBL), expressed on
antigen-presenting cells, such as activated B cells, macrophages, and dendritic cells195.
Interestingly, even though both CD4 and CD8 T cells express 4-1BB upon activation,
CD8 T cells preferentially respond to the proliferative and activating signals upon
engagement of 4-1BB. In vivo studies have shown that activation of 4-1BB drives the
proliferation of cytotoxic T cells in a graft versus host disease model, followed by robust
enhancement of IFN- and IL-2 production196. Furthermore, mice deficient in 4-1BB
cannot clear viral infections as their wild-type counterparts due to the lowered number of
cytotoxic CD8 T cells, which also have reduced virus-specific cytotoxic response. 4-1BB
deficiency does not affect the functionality of CD4 T cells in vivo197. 4-1BB lacks an
enzymatic domain, and thus relies on adaptor proteins to mediate its co-stimulatory
signals. Upon ligand binding, TRAF1 and TRAF2 proteins associate with the
cytoplasmic tail of 4-1BB leading to the activation of NF-kB signaling pathway198. NF-kB
signaling relays pro-survival signals by inducing the transcription of the anti-apoptotic
genes Bcl-xL and Bfll-1, in addition to inducing the production of cytokines such as IL-2,
IFN- and IL-4199–201. Furthermore, cytokine production is also supported by the
activation of MAPK signaling in response to 4-1BB receptor engagement202,203.
OX40. OX40 (CD134) is another TNFRSF member which expression is highly
dependent on the strength of the TCR signaling204. OX40 is only expressed on activated
CD4 and CD8 T cells. OX40 activation prolongs the expansion phase and sustains the
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effector functions of CD4 T cells, overall promoting the primary CD4 T cell response 205.
In CD8 T cells, OX40 doesn’t play a role in the initial proliferation or differentiation into
cytotoxic T cells. However, OX40 plays an important role in the effector functions of
CD8 T cells, as OX40 deficient CD8 T cells fail to accumulate during an immune
response206. Furthermore, OX40 plays an important role in memory formation for both
CD4 and CD8 T cells. In CD4 T cells, OX40 drives the generation of effector memory
populations and contributes to the production of Th1 and Th2 cytokines during recall. In
contrast, OX40 doesn’t play a role in the generation of central memory populations207. In
CD8 T cells, OX40 promotes the expression of the anti-apoptotic gene Bcl-xL and thus
controls the survival and differentiation of primed CD8 T cells into memory subtypes 208.
Like 4-1BB, OX40 also signals through TRAF adaptor proteins (TRAF2 and TRAF5) to
activate NF-kB dependent gene regulation209.
Co-Inhibitory Receptors
CTLA-4. Identified in a murine cytolytic T cell cDNA library, CTLA-4 was initially
thought to play a role in the cytotoxic response of T cells210. However, later it was found
that CTLA-4 is a negative regulator of T cell activation, upregulated only after activation
of conventional T cells but constitutively expressed by regulatory T cells. For its
activation, CTLA-4 competes with the co-stimulatory receptor CD28 for binding to B7
ligands, B7-1 and B7-2211 , but with much higher affinity212–214. Genetic deletion of
CTLA-4 in mice further showed the importance of this inhibitory receptor, as mice
deficient in CTLA-4 develop lethal autoimmune disease characterized with multiorgan
inflammation due to massive lymphoproliferation and tissue destruction, followed by
death by 3-4 weeks of age215,216. Deletion of CTLA-4 during adulthood also leads to
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rapid immune activation, multiorgan inflammation and auto-antibody production;
however, the disease severity is not lethal, implicating a role for the developmental
stage of the organism. Interestingly, deletion of CTLA-4 during adulthood leads to an
enhanced expression for other immunosuppressive molecules, such as IL-10, LAG-3,
and PD-1, suggesting that compensatory inhibitory mechanisms might also account for
the discrepancy between adult and congenital CTLA-4 deficiency217,218. One of the
major mechanisms by which CTLA-4 regulates T cell activation is signaling independent
and involves counteracting CD28 costimulatory signals by outcompeting for B7 ligands
(B7-1 and B7-2) binding, along with active removal of these ligands from the surface of
APCs219. Molecularly, CTLA-4 inactivates T cells by binding to TCR chain and reducing
its phosphorylation via binding to the phosphatase SHP-2220. Furthermore, CTLA-4 can
also inactivate Akt signaling via the serine/threonine phosphatase PP2A221. Another
mechanism by which CTLA-4 regulates T cell activation is through the control of natural
Treg cell functions. Treg-specific KO of CTLA-4 results in loss of Treg suppressive
functions which subsequently leads to systemic lymphoproliferation of effector T cells
and fatal autoimmunity on the one hand and a potent T cell-mediated tumor immunity
on the other hand222. However, rather than serving as an inhibitory receptor that
attenuates T cell activation only, CTLA-4 also provides negative co-stimulation that
limits the range of phenotypes that T cells can differentiate into. In other words, CTLA-4
constrains T cells within specific phenotypes, as loss of CTLA-4 leads to the
appearance of T cell phenotypes not observed in wild type counterparts. Furthermore,
because the loss of CTLA-4 also leads to an increase in TCR clonality, it is
hypothesized that CTLA-4 might serve as a restriction for tonic (i.e., promiscuous)
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activation of T cells by raising the threshold for activation and thus preventing the
expansion of self-reactive (i.e., promiscuous) T cell clones223.
PD-1. The first description of the programmed death-1 (PD-1) gene suggests that
PD-1 is a programmed cell death-specific inducer whose expression is increased when
thymocyte cell death is induced by activation224. However, several years later, it was
shown that PD-1 was transiently induced upon T cell stimulation through the TCR, but
rather than being involved in the induction of programmed cell death, PD-1 acts as a
negative regulator of T cells responses instead225. PD-1 is thought to play a critical role
for maintaining peripheral tolerance, as deficiency of PD-1 leads to autoimmunity
characterized with late-onset lupus-like proliferative arthritis and mild glomerulonephritis
on the C57BL/6 background, and lethal autoimmune cardiomyopathy on the BALB/c
background226,227. The severity of the autoimmune response is enhanced with age and
is highly dependent on the genetic background of the mice. PD-1 signaling is initiated
upon binding to its ligands, PDL-1 – widely expressed by both hematopoietic cells, such
as T cells, B cells, DCs and macrophages, and nonhematopoietic cells, and PDL-2 –
which expression is mainly restricted to antigen-presenting cells, such as B cells, DCs
and macrophages. Not only is PD-1 expression inducible, but so is the expression of its
ligand PDL-1 and PDL-2. While both ligands can be expressed on resting cells, their
expression is robustly upregulated in response to inflammatory signals driven by
cytokines produced by infiltrating T cells. This highlights the importance of PD-1 as a
negative feedback mechanism to dampen ongoing T cell responses by inhibiting T cell
proliferation and cytokine production. Even though PD-1 is a member of the
CD28/CTLA-4/ICOS receptor family, it shares only ~20% sequence homology with the

30
other members, mainly in its extracellular domain, but has distinct features especially in
the cytoplasmic domain228. PD-1’s cytoplasmic tail contains two critical tyrosine residues
located in the highly conserved immunoreceptor tyrosine-based motif (ITIM) and
immunoreceptor tyrosine-based switch motif (ITSM)229. The arrangement of the
cytoplasmic tail of PD-1, and the spacing between the ITIM and ITSM is in direct
resemblance to the CD33-related Siglec family of receptors expressed on most innate
immune cells. Like PD-1, Siglec receptors also deliver negative signals and dampen the
immune cell activation in an ITIM/ITSM dependent manner230. Engagement of the PD-1
receptor leads to phosphorylation of both tyrosine residues, in the ITIM and ITSM,
mainly by Lck and/or Src kinases in T cells231,232. The phosphorylated tyrosine residues
serve as docking sites for the recruitment of SH2 domain-containing phosphatases
SHP2 and SHP1229,233. SHP recruitment then leads to inhibition of T cell receptorinduced phosphorylation of TCR/ZAP70 and downstream PKC- signaling231,234, as
well as PI3K/Akt signaling following CD28 activation 221, resulting in decreased
proliferation and cytokine production. However, even though PD1 can inhibit both TCR
and CD28 signaling cascades, quantitative studies show that CD28 is the preferred
target over TCR for PD-1232. PD-1 is not expressed on naïve or resting memory T cells
and is only upregulated upon antigen-driven stimulation via the TCR. Upon removal of
the antigen, i.e., acute clearing, the levels of PD-1 decrease. However, if the presence
of the antigen is prolonged, such as during chronic infections or cancer, PD-1
expression is sustained. Transient PD-1 expression, and the subsequent dampening of
the T cell response serve as a major immunoregulatory mechanism that limits tissuerelated immunopathology. On the other hand, sustained expression of PD-1 drives T
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cell exhaustion and results in an inadequate immune response due to dysfunctional T
cells. Notably, disrupting the PD-1 signaling axis, either by blocking PD-1 or its ligands,
restores the ability of T cells to proliferate, secrete cytokines and kill altered or infected
cells235. Targeting the PD-1 signaling axis is a promising immunotherapy strategy for
treating chronic viral infections, such as HIV and HCV236,237. In the tumor
microenvironment, T cells have sustained PD-1 expression due to chronic exposure to
tumor antigens and PD-L1 upregulation on many cancer cells due to cancer cell-intrinsic
or inflammation-mediated stimuli238. Targeting this inhibitory axis has proven as a
successful immunotherapy in the treatment of several different cancers.
Section I
Checkpoint receptors play an important role in regulating the activation and
effector functions of T cells. Activating checkpoint receptors sustain and enhance the
effector functions of T cells. In contrast, inhibitory checkpoint receptors suppress and
limit the effector functions of T cells. Because of their potent immunomodulatory
functions, activating and inhibitory receptors can serve as targets for the development of
immune-based therapies. Blockade of inhibitory checkpoint receptors, such as PD-1
and CTLA-4, have already proven successful in reinvigorating the effector functions of
tumor infiltrating lymphocytes. However, such therapies are only successful in a very
small fraction of patients due to development of resistance or activation of redundant
inhibitory mechanisms. Identification of novel checkpoint receptors is imperative to allow
for the development of successful combination treatments that can target multiple
pathways and result in long term effective therapies.
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Sialic Acids
For a long time, the major macroconstituents of the cell were assumed to be nucleic
acids, proteins, and lipids. One major class of cellular components that was
disregarded, but is gaining much attention nowadays, is sugar chains or glycans. There
is a whole field of glycobiology now that focuses on understanding glycans’ molecular,
cellular, and physiological properties. It was initially thought that glycosylation happens
only on molecules secreted on the extracellular layer of cell membranes. However, this
dogma was proven wrong; instead, it was shown that many cytosolic and nuclear
proteins are glycosylated as well239,240. Defects in genes involved in efficient and precise
assembly or modification of glycans within consensus peptide sequences on proteins
have broadly been categorized as congenital disorders of glycosylation. This group of
disorders emphasizes the essential biological roles that glycosylation plays in the
normal cellular functions241. In general, glycans’ functions can be subdivided into
structural and modulatory functions or the specific recognition of glycans by glycanbinding proteins and molecular mimicry of host glycans. Glycans in the cell often
covalently bind with other macromolecules that make up the cells, more commonly
known as glycoconjugates, either glycoproteins or glycolipids. The size of the glycan in
the glycoconjugate can vary greatly, but often it is a substantial portion of the overall
mass of the molecule. This results in a very dense array of sugars, generally called the
glycocalyx. What makes glycans much more complicated than proteins is that unlike
amino acids which form one primary type of linkage in the process of generating a
polypeptide, the building blocks of glycans, monosaccharides, can generate either an

33
alpha or beta linkage to different positions of other monosaccharides in a chain, or
molecules of other type242.
Sialic acids are derivatives of the nine-carbon sugar neuraminic acid, usually
attached to the terminal position of oligosaccharide chains on glycoconjugates. Some of
the special structural features that make neuraminic acid derivatives diverse are the
amine group found at position 5 and the carboxylic group found at position 1. These
functional groups are negatively charged under physiological conditions, making
neuraminic acid a strong organic acid and thus highly reactive. Neuraminic acid without
any substitutions of the functional groups does not exist. Most frequently, the amino
group is acetylated, giving rise to the most widespread form of sialic acids, Nacetylneuraminic acid (Neu5Ac). Further substitution of a hydrogen atom in the methyl
residue of the acyl group with a hydroxyl group gives rise to another widespread sialic
acid form N-glycosylneuraminic acid (Neu5Gc). However, Neu5Gc is not found in
humans, except in pathologies, such as certain cancers. Furthermore, the hydroxyl
groups at positions 7, 8 and 9 are subject to esterification reactions with acetic acids,
which further contribute to the diversity of sialic acids. Other modifications that
neuraminic acid can undergo include adding lactoyl groups at position 9, sulfate or
methyl groups at position 8. It is important to mention that the modifications described
so far can happen in more than one position simultaneously. The variability of sialic
acids is further complemented by the type of linkage that attaches it to the underlaying
glycan. Most frequently, sialic acids are attached to the position 3 or 6 of the
penultimate sugar of a glycan chain via the C2, or position 8 of another sialic acid. The
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expression of sialic acid derivatives depends on the tissue and developmental level of
the species that express them243–245.
Sialic acids are not uniformly distributed among all species; instead, they are found
in higher vertebrates, such as echinoderms, and vertebrates. An exception are some
protozoa, viruses, and bacteria. Generally, sialic acids are expressed as part of
glycoconjugates on cell surfaces and intracellular membranes but can also be found as
a part of the serum or mucus in higher animals. The characteristic biological structure
and their unique distribution enable sialic acids to participate and fulfil important roles in
maintaining the normal homeostasis of the organism. For example, being on the
terminal end of glycoconjugates, sialic acids protect the underlying glycans and proteins
from proteases in the case of pathogen invasion. The fact that Sialic acids are densely
expressed on both the outer layer of cells and the interior of lysosomal compartments
speaks of the vital role they play in stabilizing molecules expressed on the cell
membranes and in modulating interactions with the cell surroundings. Sialic acids are
negatively charged molecules, a property that makes them an important part of
transporting ions and drugs, stabilizing the conformation of proteins, and increasing the
viscosity of mucin layers which prevents the entry of pathogens246,247.
Sialic Acids Promote Tolerance to Self by Activating Siglec Receptors
One of the most prominent characteristics of the immune system is its ability to
recognize self against non-self or abnormal self. Carbohydrates can influence the
immune system in two ways: by regulating the conformation and biological activity of
their conjugates and by serving as recognition sites for different immune cell receptors.
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As terminal moieties of glyacns, sialic acids are important recognition sites for a
family of receptors known as sialic acid-binding immunoglobulin lectins (Siglecs). Siglec
family members mediate inhibitory or activating signals upon binding to sialic acids
expressed on normal tissues or antigens. The interaction between siglecs and sialic
acids is one mechanism by which immune cells can mediate tolerance towards self and
react against unhealthy or foreign antigens. For example, de-sialyation of cellular
glycoconjugates or the lack of sialic acid expression on most microbes or virally infected
and transformed cells can serve as a signal for missing or abnormal self. Subsequently
this signal can direct immune cells to phagocytose or kill such cells and microbes.
Furthermore, sialic acids can also play a role in increasing the threshold for
activation of certain cells246–248. For example, the sialic acid receptor Siglec-2, or CD22,
counteracts the activating signals of the B cell receptor. It is postulated that by blocking
BCR signaling, CD22 helps to prevent induction of unwanted antibody response against
self-antigens249. Lastly, sialic acids also regulate the activation of the alternate
complement cascade by binding to a protein called factor H. When factor H binds to
sialic acids on normal cells, it prevents the formation of the C3 convertase and thus
prevents complement activation250,251.
Siglecs - Sialic Acid-Binding Immunoglobulin Superfamily Lectins
Siglecs are a family of immunoglobulin-type lectins that mediate proteincarbohydrate interactions specifically via sialic acids attached to glycoproteins or
glycolipids252–254. Siglecs are single pass type I transmembrane proteins that share a
high level of structural similarity. All Siglecs share a characteristic extracellular structure
that contains one V-set domain, followed by a variable number of C2-set domains253,255.
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A conserved arginine residue within the V-set domain forms a salt bridge with the
ionized carboxyl group of sialic acids, and thus is an essential part of the receptor-ligand
binding256–259. Hydrophobic interactions between aromatic amino acids from the strands of the V-set domain with the N-acetyl and hydroxyl functional groups of Sialic
acids also form important interactions that strengthen the receptor-ligand binding257.
Furthermore, there is an unusual arrangement of cysteine residues in the V-set and
adjacent C2-set domains that leads to the formation of an intra-sheet disulfide bond in
the V-set as well as a disulfide bond between the two domains260.
Most Siglecs mediate inhibitory signaling events and thus prevent immune cell
activation. The inhibitory signals are mainly mediated by the characteristic cytoplasmic
tail of SIglec receptors, consisting of conserved intracytoplasmic immune-receptor
tyrosine-based inhibitory motifs (ITIM), defined by the consensus sequence I/LVxYxxL/V
(x can be any amino acid)261 and an immune-receptor tyrosine-based switch motif
(ITSM), defined by the consensus sequence TIYxxI/V262–264. Some Siglecs, such as
human Siglec 10, contain the consensus sequence YL/V/LNV/P, which binds the
adaptor protein Grb2 and participates in the Ras signaling cascade265. Other Siglecs,
such as Siglec 14, 15 and 16, lack a cytoplasmic signaling domain and instead pair up
with the adaptor protein DAP12 via a positively charged lysine residue in the
transmembrane region which have immune receptor tyrosine-based activating motifs
(ITAMs), allowing them to participate in directly activating or enhancing signaling
cascades266–268.
Based on the evolutionary conservation among species, the Siglec family of
receptors can be divided into two sub-groups. Siglecs common to all species are Sialo-
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adhesin, or Siglec-1, CD22, or Siglec-2, and MAG, or Siglec-4a. In contrast, the CD33related Siglecs are species-specific, rapidly evolving and include Siglec-3 and Siglec-511 and -14-16 in humans, and Siglec-3 and E-H in rodents. Among the CD33-related
Siglecs, all but Siglec-14, -15 and -16, are characterized by having the conserved ITIMs
in the cytoplasmic tails266. Sequence comparisons of the CD33rSiglecs in multiple
mammalian species show that these Siglec genes have undergone rapid evolution by
gene duplication, deletion and chimerism, as well as the selection of sequence domains
that recognize only certain glycan structures269.
Each Siglec is unique in that they have strong preferences to bind sialic acids
based on the nature of the sialic acid, the type of glycosidic linkage, as well as the
underlying glycan. Siglecs are mainly expressed on hematopoietic and immune cells.
Most human and mouse immune cells express at least one type of Siglec, with others
expressing multiple. Even though some Siglecs show unique cell expression, most have
overlapping distribution across leucocytes, suggesting that they have specific and nonoverlapping functional properties. Because each Siglec shows specificity for a unique
pattern of sialylation, it is likely that each receptor has a unique function. Little to no
expression has been reported for resting T lymphocytes of healthy humans, an
exception being Siglec-7 and -9, which can be found in a small population of CD8+ T
cells and mediate direct inhibition of TCR signaling 270,271. Transfection studies of Siglec7 and -9 into Jurkat T cells shows direct inhibition of T cell receptor signaling,
suggesting that Siglec expression in T cells might regulate the cell activation 272. In some
pathologies though, Siglec expression in the T cell compartment can be altered. For
example, a recent study shows that tumor-infiltrating lymphocytes from melanoma
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patients have high expression of Siglec-9. The expression of Siglec-9 was inversely
correlated with the clinical outcome and prognosis of disease 273. Furthermore, HIVinfected patients have a greater frequency of circulating CD4+ T cells expressing
Siglec-5 and -9, in contrast to healthy patients274.
Siglec-5
Siglec-5 structure. Siglec-5 was cloned in 1998 by Paul R. Crocker’s group from
a human macrophage cDNA library. The newly discovered gene showed remarkable
similarity with the human CD33 cDNA. Using in situ hybridization, the gene for Siglec-5
was mapped to chromosome 19q13.41-q13.43, a region where many other Ig
superfamily members are also localized275. Siglec-5 is a 551 amino acids long type-1
transmembrane protein that belongs to the Immunoglobulin superfamily. Extracellularly,
Siglec-5 comprises of a N-terminal V-set domain followed by three C2-set domains.
Within the extracellular sequence, Siglec-5 carries eight potential N-linked glycosylation
sites. It is hypothesized that glycosylation regulates Siglec-5 ability to discriminate sialic
acids276. Like the other members of the Siglec family, the unique pattern of cysteine
residues within the V-set domain is also conserved in Siglec-5. More specifically, the
unusual intra-sheet disulfide bond between the B-E strands of the V-set domain, as well
as an interdomain disulfide bond between Cys41 from the B strand of the V-set to
Cys175 from the B-C loop of the C2-set domain are present in the Siglec-5
structure260,277,278. While this interdomain linkage is not directly involved in ligand
binding, it is thought to impose flexibility limitations of the carbohydrate-binding domain.
Siglec-5 has a single transmembrane domain that links the 4 extracellular Ig-like
domains to an 89 amino acids long cytoplasmic tail that has two tyrosine-based

39
conserved motifs. The first motif, LHYAS/VL, is homologous to the consensus sequence
for the immunoreceptor tyrosine-based inhibitory motif (ITIM), I/L/VxYxxL/V. The second
motif, TEYSEI/V, resembles an immunoreceptor tyrosine-based switch motif (ITSM) that
is also described in some immune cell proteins. Molecular characterizations of Siglec-5
showed that the protein exists as a homodimer on cell surfaces277.
Siglec-5 ligands. Most Siglecs show a preference for one glycosidic linkages of
sialic acids, but Siglec-5 is more promiscuous and binds equally well to both 2,3- and
2,6-linked, and to a lesser degree 2,8-linked sialic acids277–279. As reported for other
Siglecs, the conserved Arginine residue in the G strand in the V-set domain plays a
critical role in Sialic acid recognition; the Arginine binds the carboxyl functional group
and neutralizes the negative charge of the Sialic acid, whereas the G strand forms a
beta sheet-like hydrogen bonds with the glycerol side chains of Sialic acids. The reason
for the variability of Siglecs recognizing different Sialic acid linkages arises from the
interaction of Sialic acids with the highly different residues found in the GG’ and CC’
regions of the V-set domains278.
A study by Rie Suematsu et al. identifies lipophilic ligands specific for Siglec-5, in
addition to sialic acids. Here the authors show that Siglec-5 binds to lipids compounds,
such as alkanes and triacylglycerols, made by the fungal species Trichophyton. Further,
they identify several endogenous lipid-based ligands, among which most prominent are
the mitochondrial lipid cardiolipin and the anti-inflammatory lipid 5-palmitic acidhydroxysteric acid. Interestingly, lipid binding by Siglec-5 requires the hydrophobic Nterminal stretch, which is dispensable for Sialic acid binding280.
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Several protein ligands of Siglec-5 are also described in the literature. -protein
expressed in Group B Streptococcus281,282, and Hsp70283 mediate immunomodulatory
effects via binding to Siglec-5.
Siglec-5 isoforms. A unique characteristic of Siglec-5 is that it has isoforms
produced by alternative splicing of the extracellular and intracellular sequence. The
original Siglec-5 sequence cloned by Paul Crocker’s group is designated as the full
length, or hSiglec-5 4-L, where 4 stands for having four Ig set domains, and L stands for
the full-length of the cytoplasmic tail, including the ITIM and ITSM. The first isoform is
identical to the Siglec-5 4-L in its extracellular sequence; however, it has a truncated
cytoplasmic tauk of 38 amino acids which lacks the ITIM and ITIM-like motifs. This
isoform was named Siglec-5 4-S, where S designates the short cytoplasmic tail. The
second isoform has a variation in the extracellular domain and lacks one of the three
C2-set domains. This isoform is designated Siglec-5 3-L. The third isoform has an unspliced intron between the second and third C2-set domains, which introduces a
premature stop codon in the extracellular sequence of Siglec-5. This isoform is
predicted to encode a soluble truncated protein that has the extracellular sequence of
Siglec-5 and is designated hSiglec-5-3C284.
Tissue distribution. Tissue distribution of the full-length Siglec-5, and its Siglec5-4S isoform, is mainly confined in immune tissues, such as bone marrow, spleen and
peripheral blood, but at lower levels can also be found also in the lymph nodes,
appendix, placenta, lung, thymus, pancreas, and fetal liver277,284. The variants Siglec-53L and Siglec-5-3C are also detected in immune-related tissues, but at much lower
levels284. The functional significance of the different Siglec-5 isoforms is not clear, but
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perhaps the differential tissue distribution might influence their function. Among
leucocytes, Siglec-5 is expressed on monocytes, neutrophils, dendritic cells, subsets of
tissue macrophages, and B cells, but not T cells or NK cells277,285.
Function. Siglec-5 plays diverse physiological roles related to 1) signaling and
recognizing pathogens and self-associated signals, 2) cell-cell interactions and 3)
endocytosis of ligands.
Signaling and recognition of pathogens. Siglec-5 is an inhibitory receptor that
blocks activating signals in innate immune cells, monocytes, neutrophils, and
macrophages specifically. Engagement of Siglec-5 with its ligands results in the
recruitment of tyrosine phosphatases SHP-1 and SHP-2 to the ITIM and ITSM within its
cytoplasmic tail. Using transfected rat basophil leukemia (RBL) cells Avril, T. et al. first
showed that the recruitment of SHP-1 and SHP-2 results in inhibitory signals leading to
reduced calcium flux and serotonin release after co-ligation of the activating FCRI
receptor. Interestingly, inhibitory signaling events following Siglec-5 receptor
engagement occur even in the absence of phosphorylation of the tyrosine residues
within the ITIM and ITSM motifs. These observations suggest several hypotheses that
need further testing: 1) that the mechanism by which Siglec-5 initiates inhibitory signals
is independent of the ITIM/ITSM and protein-tyrosine phosphatase pathway; and 2) that
weak interactions between SHP-1 and SHP-2 occur even with non-phosphorylated ITIM
and ITSM motifs within Siglec-5, and are sufficient to trigger inhibitory signals via the
phosphatase activity286.
Most functional studies of the mechanism of Siglec-5 activation and signaling, as
well as the biological outcomes, come from the assessment of Siglec-5 contribution to
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bacterial pathogenesis. Pathogenic bacteria have evolved to use sialic acids as a
molecular mimicry mechanism to avoid immune cell activation, by either escaping
recognition, or activating of inhibitory immune cell receptors from the Siglec family.
Several human pathogens, such as Neisseria meningitidis, Campulobacter jejuni and
Group B streptococci (GBS) have been shown to engage Siglec-5, among other
members of the Siglec family. These pathogens engage the SIglec-5 receptor mainly in
a sialic acid dependent manner in order to suppress the activation of immune cells
289
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Interestingly, certain strains of GBS engage Siglec-5 in a Sialic acid-independent

manner and instead use protein/protein interactions via the surface -protein. Upon
binding to -protein, Siglec-5 accumulates at the point of contact with GBS and triggers
a signaling cascade that begins with phosphorylation of the cytoplasmic tail and
subsequent recruitment of SHP protein tyrosine phosphatases, SHP-1, and SHP-2.
These events result in resistance to bacterial killing and phagocytosis by leucocytes. In
neutrophils specifically, these events lead to impaired innate immune functions, such as
weaker oxidative burst, decreased neutrophil extracellular traps release, and reduced
production of cytokines such as IL-8281,282. Furthermore, even though GBS attaches on
phagocytic cells the bacteria are not phagocytosed. It is thought that the recruitment of
SHP1 and/or 2 to the cytoplasmic tail of Siglec-5 negatively regulates the phagocytosis
pathway as well290. The role of SHP1 in the regulation of Fc- receptor-mediated
phagocytosis has been well established, where SHP-1 is implicated in a direct blockade
of phagocytosis activating signals mediated by the SRC family kinase Syk, the ubiquitin
ligase Cbl, phosphatidyl inositol-3 (PI-3) kinase, and Rac291. Even though SHP-2 is the
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phosphatase to be recruited more specifically after Siglec-5 activation, it is possible that
in this scenario SHP-2 undertakes a similar signaling pathway as previously described
for SHP-1 to block pathogen phagocytosis.
Signaling and recognition of self-associated signals. Several reports now
show that Siglec-5 acts as a receptor for self-associated signals and thus regulates the
inflammatory response. The heat-shock protein 70 kDa (Hsp70), a known intracellular
chaperon, is described to modulate the immune response by engaging Siglec-5. It was
shown that Siglec-5 interacts with intracellular Hsp70 from cell lysates as well as
secreted Hsp70 from activated monocytic cell lines. Furthermore, Hsp70 also
suppresses the inflammatory response of monocytic cells via activation of Siglec-5.
Using Siglec-5 expressing THP1, a monocytic cell line, it was shown that LPS
stimulation in the presence of Hsp70 leads to a decrease in inflammatory cytokine
production, such as TNF- and IL-8283. Other self-associated signals that suppress the
immune response via binding to Siglec-5 are the mitochondrial protein cardiolipin and
the endogenous lipids PAHSAs. Using reporter assays, these studies have shown that
engagement of Siglec-5 by these lipophilic ligands contributes to an anti-inflammatory
response mediated by innate immune cells such as monocytes280.
Endocytosis of ligands. Like most CD33-related Siglecs, Siiglec-5 also serves
as an endocytic receptor that clears sialylated antigens which could result in either
enhancing or suppressing antigen presentation. While not completely understood, it is
predicted that the endocytic functions of Siglec-5 are regulated via its tyrosine-based
internalization signals292 within the ITIM and ITSM. For example, sialylated N.
meningitidis is internalized in a Siglec-5 dependent manner. However, whether uptake
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of the bacteria is beneficial for clearance, or the internalization route simply allows for
bacteria to survive and translocate within the phagocytes remains to be explored 289.
Another example of Siglec-5 mediated endocytosis is the internalization of coagulation
factor VIII (FVIII) and von Willebrand factor (VWF), essential proteins for blood clotting.
Clearance, and thus regulation of plasma levels of FVIII/VWF complexes depends on
Siglec-5 mediated uptake, in addition to other well-recognized receptors such as LDLreceptor related protein-1, LDL-receptor and asialoglycoprotein293. More specifically,
overexpression of Siglec-5 in cell lines, such as HEK293t, results in uptake of
FVIII/VWF complex. In vivo studies using overexpression of Siglec-5 in murine
hepatocytes also show the downregulation of FVIII/VWF circulating levels 294.
Cell-cell interactions. Cell-cell interactions refer to the interaction of molecules,
ligands, and receptors on the surface of cells. This represents a mechanism of
communication that cells use to respond to environmental signals. Some cell-cell
interactions are permanent, such as the formation of tight junctions between epithelial
cells; others are transient, such as immune cells being recruited to an inflammatory site.
The migration of cells from one site to another is tightly regulated by the selective
expression of adhesion and signaling molecules within the cells of the vascular
systems. Different members of the selectin family of adhesion proteins mediate the
tethering, rolling and extravasation of leukocytes. These processes are enabled by
interactions of selectins with the counter-receptor carbohydrate ligands expressed on
the surface of leucocytes. Siglec-5 regulates cell-cell interactions by binding to Pselectin glycoprotein-1 (PSLG-1). PSLG-1 is a transmembrane protein that plays a
crucial role in the initial recruitment and rolling by interacting with P and E selectins
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expressed on endothelial cells lining up the vasculature. Importantly, PSLG-1 is heavily
glycosylated and the sialic acids expressed on the glycan termini are crucial for selectin
interactions295,296. Siglec-5 directly binds to PSLG-1 in a sialic acid-dependent manner;
in vivo studies confirm that soluble Siglec-5 reduces rolling and prevents recruitment of
leukocytes at a sterile inflammation site297. It is possible that Siglec-5 binds to other Pselectin ligands as well, but more studies are needed to confirm this hypothesis. From a
physiological standpoint, it is possible that Siglec-5 binds P selectin PSLG-1 to regulate
excessive leukocyte rolling under homeostatic conditions. It is known that Siglecs
interact with sialic acid-containing glycoconjugates under resting conditions and unmask
such proteins or lipids upon cell stimulations. Thus, it could be that Siglec-5 binds to
PSLG-1 or other P- and E-selectin ligands under resting leukocyte states but release
the ligands upon stimulation to enhance leukocyte rolling. Furthermore, healthy human
plasma contains about 75ng/ml of the soluble isoform of Siglec-5, Siglec-5-3S, but can
increase 2-3-fold under pathological conditions, such as acute myeloid leukemia298 or
sepsis299. This could also suggest that increased levels of soluble Siglec-5 can
contribute to pathologies by blocking leukocyte migration towards sites of infection.
In addition to regulating leucocyte rolling, soluble Siglec-5 binds and activates
PSGL1 expressed on activated CD8 T cells. Subsequently, activation of PSGL-1
manifests with its well-known immune-checkpoint roles that promote CD8 T cell
suppression and exhaustion. In a scenario such as sepsis, where soluble Siglec-5
levels are significantly increased, this could provide a mechanism for both reduced
recruitment and functionality of leucocytes that leads to reduced pathogen clearance 299–
301.
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Siglec-5 and -14 – a Paired Receptor System
Siglec-14, another member of the CD33-related subgroup of Siglecs, has nearly
identical ligand-binding domain with Siglec-5 but lacks the cytoplasmic signaling tail.
Instead, Siglec-14 pairs with the adaptor protein DAP12 and mediates activation signals
and is thought to be the pairing, activating receptor for Siglec-5266. Interestingly certain
people lack Siglec-14 due to a fusion between the Siglec-14 and Siglec-5 genes, which
gives rise to a new gene, Siglec-14/5. This fusion gene is identical to the coding
sequence of Siglec-5; however, its expression is controlled under the Siglec-14
promoter. So there is a polymorphism within the human population, where people have
both Siglec-5 and Siglec-14, or lack one or both alleles of Siglec-14 as it is replaced
with the fusion gene Siglec-14/5302. Being an activating receptor, Siglec-14 enhances
the responsiveness of immune cells to bacterial pathogens, and thus Siglec-14
polymorphism is advantageous for microbial survival and makes the host more
susceptible to infections. The presence of pairing inhibitory and activating receptors in
immune cells is not well understood but is thought to be a mechanism to fine-tune the
immune response. Protein expression of Siglec-5 and Siglec-14 overlaps partially, and
subpopulations of monocytes and neutrophils expressing one or the other exist as well.
The fact that Siglec-14 counteracts the inhibitory effects of Siglec-5 in both monocytes
and neutrophils is supporting evidence that the two are pairing receptors. In monocytes,
inflammatory activation with LPS increases Siglec-14 mRNA levels at the expense of
downregulating Siglec-5 mRNA. We can speculate that regulation at the level of
receptor expression level maintains the balance between Siglec-5 and Siglec-14
activity, but further evidence is needed to prove it303. Evolutionarily, we can also
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speculate that Siglec-14 emerged to compete with Siglec-5 binding ligands that
generally would suppress the immune responses, thus balancing out the innate immune
response to pathogens carrying such ligands.
However, Siglec-5 and Siglec-14 have unique sequences within their
extracellular domains which might influence some of their ligand binding affinities or
preferences. For example, a new study shows that Siglec-14 uniquely binds to
sialylated glyco-RNA molecules expressed on cell surfaces, while Siglec-5 does not304.
These observations suggest that even though Siglec-5 and Siglec-14 act as paired
receptors and mediate opposing responses to the same ligand, they also have unique
functions independent of each other.
Section II
Where, when, and how latent TGF-β is activated is not well understood. Several
studies suggest that active TGF-β is expressed on cell surfaces329,339. However, the
sequence of active TGF-β lacks a cell-binding domain, raising the question of how it is
anchored to cell surfaces. Although several anti-TGF-β antibodies are commercially
available, detection of cell surface-bound active TGF-β remains challenging and is not
well documented. The most widely used, 1D11 antibody clone serves well for
neutralizing TGF-β, but not for immunofluorescent detection purposes. Altogether, this
technical hurdle leaves a knowledge gap in the TGF-β field.
Transforming Growth Factor- (TGF-)
In 1979, de Larco and Todaro described the presence of growth factors in
supernatant fluids of sarcoma transformed mouse 3T3 cells that cause normal
fibroblasts to become transformed by growing anchorage-independent colonies in soft
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agar. These factors, termed transforming growth factors, were described to act as
proximal effectors of transformation, as their removal reversed the phenotype305. By
1981, the transforming factor -  was purified and characterized by the teams of Harold
Moses, and Michael Sporn and Anita Roberts306,307. Initially thought to be only produced
by neoplastic cells, TGF- than was also isolated from normal, non-neoplastic cells308.
By 1982, Joan Massague provided evidence for a high-affinity receptor for TGF- 309.
Using collaborative effort, it was established that there are three TGF- receptors, now
known as type I, type II and type III - a co-receptor also known as  glycan310,311. Unlike
other described growth factors at that time, TGF- was the first multifunctional growth
factor. In addition to stimulating growth and transformation, TGF- also inhibited the
proliferation of primary and secondary cell cultures. Furthermore, TGF- also induced
cellular differentiation in some cell types while blocking it in others. Thus, it was
apparent that the function of TGF- must be evaluated based on the context of other
signals present.
Latent TGF-
TGF- is secreted from cells in a biologically latent form as a part of high molecular
weight protein complex that has to be activated to perform its biological effects312.
Because the receptors for TGF- are ubiquitously expressed, this is an important
biological property, as it limits the cellular targets of TGF- to those cells that can either
directly or indirectly activate the latent form. Active TGF- is a 25kDa homodimer linked
by Cys77 disulfide bonds and derived by proteolytic cleavages of a larger precursor
polypeptide313,314. Upon synthesis of the pre-pro-protein in the endoplasmic reticulum
(ER) the signal peptide of the sequence is quickly removed, generating a pro-TGF-
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that undergoes N-glycosylation at predicted sites. Pro-TGF- then translocates into the
Golgi apparatus where it is processed by proteolytic digestion. Furin, an endopeptidase,
cleaves the pro-protein at a consensus motif comprising of R-H-R-R sequences found
at the junction between the pro-region and immediately before the N-terminal Ala
residue of the mature growth factor315. This proteolytic event leads to two products, one
a dimer of the N-terminal region, called latency-associated peptide (LAP), and two, a
dimer of the C-terminal portion, the mature TGF-. Despite the cleavage, the pro-region
of TGF- is essential for the folding and assembly of the mature dimer. More
specifically, Cys 223 and 225 mediate disulfide linkage and assembly of dimeric LAP,
which then non-covalently associates with the mature TGF- dimer and generates the
small latency complex (SLC)316–318. When part of the latent complex, TGF- cannot bind
to its receptors and thus is referred to as inactive. While in the ER, the dimeric pro-TGF is covalently linked to milieu proteins, such as members of the latent TGF- binding
protein (LTBP) family, LTBP1, 3 or 4. LTBPs are a family of proteins related to
extracellular matrix (ECM) proteins and are characterized with unique 8-Cys-like
repeats. A disulfide bond between the 3rd 8-Cys repeat of LTBPs and Cys 33 of LAP
links LTBP to the SLC, giving rise to the large latent complex (LLC). The pro-TGF-
dimer that gives rise to the SLC can be secreted directly by some cell types; however,
the covalent linkage with LTBP enhances the secretion, and thus is suggested to play a
chaperone-like function in that it enhances the proper folding, secretion, and targeting to
the ECM of the pro- TGF- dimer318,319. While the milieu molecules LTBPs store proTGF- in the ECM, another group of proteins, leucine-rich-repeat-containing proteins
(LRRC) store the complex on the cell surface. Two LRRC proteins, LRRC32 and

50
LRRC33, have been described so far. LRRC32, also known as glycoprotein-A
repetitions predominant protein (GARP), is expressed on platelets, endothelial cells and
some immune cells, such as activated regulatory T cells and dendritic cells320,321.
LRRC33 is specifically expressed in macrophages, especially in microglial cells 322.
Overall, LTBPs expression is ubiquitous, compared to the more cell-specific expression
of GARP and LRRC33. The differential expression of milieu molecules that associate
with latent TGF- thus provides localization and selective activation in specific cells
only. Based on the crystal structure solved by Tim Springer’s group, latent TGF- exist
in a ring-like structure, where the arm domains of LAP connect at the elbows with
crossed “forearms” formed by the dimer of mature TGF- and the LAP “straitjacket”
elements that surround each of the mature TGF- monomers. LAP arms are connected
at the neck via di-sulfide bonds and each shoulder carries and RGD motif, essential for
integrin binding. On the opposite side, where the “straitjacketed” arms of mature TGF-
are crossed, LTBP binds to the straitjacket323.
Conversion of latent to biologically active TGF-. Regulation of the amount of
active TGF- is crucial for health in mammals. Too little or too much TGF- is
incompatible with life. Mice that lack either of the TGF- isoforms do not survive past
few days or weeks after birth. On the other hand, overexpression of TGF- is embryonic
or soon after birth lethal, resulting from organ-specific or generalized pathologies.
Because TGF- synthesis and receptor expression are ubiquitous, the major regulatory
step of TGF- activity occurs at the level of converting latent into active TGF-.
Proteolytic activation. Several protease families are reported to activate latent
TGF-, including plasmin, MMP-2, and MMP-9. MMP9 and MMP2 are metalloproteases
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that require cell surface localization to proteolytically activate latent TGF-. In the case
of MMP-9, cell surface localization is mediated by binding to CD44, a hyaluronan
receptor, whereas MMP-2 is docked to the cell surface by V3 integrin. Even though
MMPs are noted as key players in tumor advancement and tissue remodeling via ECM
proteolysis, their expression is also induced in normal stromal cells during tissue injury
and repair. This could suggest that MMP-9 and MMP-2 are involved in activating TGF-
as a physiological mechanisms of tissue remodeling and this mechanism is adopted by
cancer cells to promote their growth and invasion 324. Plasmin, on the other hand, is a
serine protease that activates latent TGF- by proteolytic degradation of LAP325,326.
However, mice that lack the genes involved in the proteolytic activation of TGF- do not
show any phenotype like TGF- deficiency. This could result from a redundancy in
activating enzymes or involvement of additional proteins or mechanisms of activation.
Activation by thrombosponding-1. Thrombospondin-1 (TSP1) is a disulfidelinked homotrimer secreted by many cell types shown to associate with both the LLC
and SLC and activate TGF-. The unique sequence within TSP-1, RFK, binds to the Nterminal region of LAP and causes a conformational change that makes the mature
TGF- peptide accessible to the receptors. According to this model, TGF- is never
released from the latent complex; instead, the conformational changes in the complex
only expose the mature TGF- upon binding to TSP-1. A strikingly similar pathology is
observed between mice that lack TSP-1 or TGF-1 in multiple organ systems, but
especially the lungs and pancreas. These similarities are attributed to the lack of
activation of TGF- by TSP-1 and strengthen the conclusion that TSP-1 regulates TGF activation in vivo. It is thought that TSP-1 mediated activation of TGF- is important
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for maintaining the basal levels of active TGF- needed for normal growth and
development327,328. Furthermore, TSP-1 activity can be coupled with proteolytic
enzymes to enhance the activation of latent TGF-. It is demonstrated that the
proteolytic efficiency of enzymes is enhanced if the protease-substrate complex is
localized to the surface of the cell, and thus it is shown that surface anchoring of TSP-1
and latent TGF- increase the levels of active TGF-. TSP-1 is a natural ligand for
CD36, a surface glycoprotein expressed by monocytes and macrophages. Besides
being involved in platelet-monocyte/tumor adhesion, platelet aggregation and
macrophage uptake of apoptotic cells, the interaction between TSP-1 and CD36 is also
important for activating latent TGF-. The proposed model for this type of latent TGF-
activation is that TSP-1-latent TGF- complex localizes at the cell membrane by
association with CD36. From here either TSP-1 proteolytic activity or cell-generated
plasmin, a serine protease can then liberate active TGF- to bind to its receptors329.
Activation by integrins. Integrins are surface heterodimeric proteins composed
of non-covalently associated  and  subunits involved in binding extracellular ligands
to the cytoskeleton to mediate cell adhesion and migration. Among the 24 vertebrate
integrins described, two integrins, V6 and V8, are specialized in efficiently
activating latent TGF- in vivo. Mice lacking either of V6 or V8 recapitulate all
major phenotypes of TGF-1 null mice330. V6 and V8 integrins interact with
conserved RGD motifs of LAP and represent another major mechanism for TGF-
activation. Mice carrying an RGD to RGE mutation in the LAP sequence have a
selective loss in integrin-mediated TGF- activation, despite producing normal levels of
latent TGF-, and also recapitulate all major phenotypes of TGF-1 null mice331. Even
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though multiple mechanisms of TGF- activation are described, integrin recognition of
RDG motifs in LAP play a crucial role in TGF- activation. However, different
mechanisms of latent TGF-1 activation have been proposed for the two integrins. In
the case of V6 integrin, the cytoplasmic domain of the  chain interacts with actin
filaments which exerts tensile forces that lead to conformational changes in the latent
complex. Whether this physical pulling only exposes or completely releases TGF- is
not well understood. Based on the crystal structure of latent TGF-, it is proposed that
TGF- must be liberated. If integrin binding and physical force only change the
conformation of the latent complex such that mature TGF- is exposed, this is only
enough for binding of the type II TGF- receptor. Type I receptor binding overlaps with
many of the interactions between TGF- and the arm domains of LAP and thus a
complete release from LAP would be required for receptor engagement323. V6 is
expressed at low levels on epithelial cells but in response to inflammation or injury the
expression increases. Subsequently, the activation of TGF- can mediate suppression
of the inflammation332. V8, on the other hand, mediates TGF- activation in a
protease-dependent manner. It is suggested that in this scenario, the integrin is
necessary to concentrate latent TGF- on the cell surface which allows proteases, such
as the MMP membrane type 1 (MT1), to proteolytically degrade LAP and release active
TGF- 333,334. V8 is expressed by epithelial cells, fibroblasts, neurons, as well as
immune cells such as glial cells, dendritic cells, and CD4+ T cells. One of the
mechanisms human regulatory T cells use to induce tolerance and suppress
inflammatory responses is TGF- activation. Interestingly, even though latent TGF- is
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expressed at similar levels between both helper and regulatory T cells, the integrin
V8 is expressed at significantly higher levels in activated regulatory T cells, compared
to helper T cells. Even though the proposed mechanism for TGF- activation by V8
involves proteolytic degradation of LAP, crystal structure analysis shows that the
residues that 6 uses to bind to TGF-, are conserved in 8 only, and no other integrin
 subunits335. So it is possible that V8 also uses pulling forces on LAP to liberate
active TGF-336.
Activation by reactive oxygen species. The first evidence that reactive oxygen
species (ROS) regulate TGF- activation come from studies using irradiation of
mammary gland cells. These studies show that irradiation induces a rapid shift from
latent into active TGF-. Ionizing radiation generates hydroxyl radicals and other ROS,
which alter the conformation and stability of the latent complex and enable TGF-
activation. It is speculated that the mechanism of activation by ROS is by protein
oxidation which results in loss of the non-covalent association between LAP and mature
TGF- 337,338.
TGF- Signaling
Activation and regulation of receptors and Smad molecules. The mature
TGF- dimer, liberated from the latency complex, binds to a pre-formed homodimer of
TRII. TGF- bound by TRII is then recognized by TRI homodimer, which is recruited
to the complex and leads to the formation of a hetero-tetrameric TRI-TRII receptor
complex340,341. Both TRI and TRII are dual-specificity kinases that contain a
cytoplasmic serine/threonine and tyrosine kinase domain 342. TRII is constitutively
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active and autophosphorylation of at least three critical serine residues plays a critical
role in the regulation of the receptor kinase activity343. Ser213, located in the
membrane-proximal region is phosphorylated via an inter-molecular mechanism and is
suggested to cause conformational changes in the kinase domain of TRII, resulting in
kinase domain activity. Autophosphorylation of Ser409 and Ser416 requires
dimerization of the TRII and occurs via intra-molecular mechanisms. Interestingly,
while phosphorylation of Ser409 leads to a stimulatory, phosphorylation of Ser416 has
an inhibitory effect on the receptor kinase activity by regulating the phosphorylation
state of the TRI. Because the negative charge acquired during Ser409 phosphorylation
is not enough to mediate TRI phosphorylation, it is suggested that Ser409
phosphorylation changes the conformation of the kinase region, thus affecting its
substrate binding sites. In contrast, phosphorylation of Ser416 is thought to cause a
conformational change that is unfavorable for the kinase region activity 344. Additionally,
TRII auto-phosphorylation on tyrosine residues Tyr259, 336 and 424 is also essential
for receptor kinase activity342. However, TGF- binding to TRII is not enough to trigger
receptor signaling, besides TRII always being catalytically active; instead, it causes the
recruitment of TRI which is then trans-phosphorylated by TRII kinase. Serine and
threonine residues located in the glycine-serine (GS) rich domain preceding the kinase
domain of TRI are the major sites of phosphorylation by TRII. Phosphorylation of the
GS domain not only increases the TRI kinase activity but also converts the GS domain
from a binding site for the inhibitory protein FK506-binding protein 1A (FKBP12), to an
efficient recruitment motif for its direct substrates, a family of intracellular signaling
molecules known as Smads345–349.
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Canonical TGF- signaling. TGF- signaling mediates its effects by regulating
gene expression via receptor-regulated activation of Smad proteins. Smads are a family
of proteins that are ubiquitously expressed in all adult tissues. Functionally, Smads can
be divided into three subfamilies: 1) receptor-activated Smads (R-Smads: Smad1, 2, 3,
5 and 8) get recruited to the activated TRII- TRI complex, and become
phosphorylated by TRI; common mediator Smads (Co-Smads: Smad4) which
oligomerize with phosphorylated R-Smads; and inhibitory Smads (I-Smads: Smad 6 and
7), which compete with R-Smads for TR binding but also mark the receptors for
degradation. Structurally, Smad proteins have two conserved domains, an N-terminal
Mad homology 1 (MH1) and C-terminal Mad homology 2 (MH2) domain, connected by a
linker region of variable length and sequence. The MH1 domain is highly conserved
among the R- and Co-Smads, but not I-Smads and regulates the import of Smads into
the nucleus, as well as their transcriptional regulation via binding to DNA and nuclear
proteins. MH2 on the other hand is highly conserved among all Smad sub-families and
regulates Smad oligomerization, interaction with TR, and cytoplasmic adaptor proteins.
Inactive, cytoplasmic Smads are autoinhibited by an intramolecular interaction between
the MH1 and MH2 domains350. Upon activation of the TR complex, TRI specifically
recognizes and phosphorylates the R-Smads, Smad2 and Smad 3 at serine residues
within the conserved SSXS C-terminal region. Recruitment of Smad proteins to the
receptor complex is mediated by double zinc finger, or FYVE domain, containing
proteins, one of them being Smad anchor for receptor activation (SARA). Through the
FYVE domain, SARA binds to phosphatidylinositol 3-phosphate and thus organizes
inactive Smad proteins to the plasma membrane or endosomal vesicles. Through the C-
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terminus, SARA can bind to the activated TGF- complex and thus can serve as a
bridge between the R-Smads and the receptors351. Another FYVE domain protein,
hepatic growth factor-regulated tyrosine kinase substrate (Hrs/Hgs), cooperates with
SARA in the recruitment of Smad2 and Smad3 to the receptor complex and thus
contributes to TGF- signaling352. Once phosphorylated, R-Smads are ready for nuclear
translocation, as nuclear localization signals (NLS) become exposed. In the case of
Smad3, a conformation change exposes a five-residue NLS motif on the N-terminus,
which is essential for a nuclear import via an importin-beta/Ran pathway353,354. On the
other hand, the conformational change upon Smad2 phosphorylation reduces its affinity
for the Smad binding protein SARA and thus unmasks its nuclear import activity355.
Furthermore, upon phosphorylation of the R-Smads, the TR – Smad interaction is
weakened and leads to dissociation of the two protein complexes. In response to TGF, activated Smad2 and Smad3 then associate with the Co-Smad, Smad4, forming a
functional oligomer that translocates to the nucleus356–358. In the nucleus, R-Smad/CoSmad complexes regulate gene transcription directly by binding to the DNA sequence,
or indirectly, by interacting with DNA binding proteins and transcriptional co-activators or
co-repressors. One of the key molecules involved in the regulation and fine-tuning of
TGF- signaling is the inhibitory Smad, Smad7. At basal states, Smad7 resides in the
nucleus, from where it translocates into the cytoplasm upon TGF- stimulation359.
Smad7 associates with TRI and antagonizes TGF- signaling via several different
mechanisms, such as blocking R-Smad recruitment360,361 to TR, promoting dephosphorylation of TR362, ubiquitination and degradation of TR 363,364, as well as
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blocking R-Smad/Co-Smad complexes from interacting with DNA target sequences in
the nucleus365.
Non-canonical TGF- signaling. Non-canonical TGF- signaling involves a
non-Smad related signaling cascade that activates different branches of the mitogenactivated protein (MAP) kinase pathway, such as extracellular signal-regulated kinase
(ERK), c-Jun amino-terminal kinase (JNK), p38 MAP kinase; Rho-like GTPase signaling
pathways, and phosphatidylinositol-3-kinase/AKT pathways. Being dual-specificity
kinases, upon tyrosine phosphorylation, the TGF- receptors can serve as sites for
recruitment of Src homology 2 (SH2) domain-containing proteins. Recruitment of
signaling mediators is thought to enable TGF- receptors to trigger non-Smad-related
signaling pathways366.
TGF-β in Cancer
Most advanced human cancers overexpress TGF-β. During the early stages of
tumorigenesis, TGF-β has an anti-proliferative effect on the tumor cells, thus restricting
tumor growth. However, later, tumor cells become refractory to TGF-β cytostatic effects
and re-purpose the TGF-β signals for tumor progression pathways. Additionally, by
overproducing TGF-β, cancer cells exploit TGF-β’s immune regulatory role to subvert
the anti-tumor immune response. TGF-β mediates escape from T cell immunesurveillance by directly repressing the T cell cytotoxic program 367,368, favoring regulatory
T cell differentiation369, as well as restricting trafficking of anti-tumor T cells into the
tumor microenvironment (TME)370,371. Because of its pro-tumorigenic effects, TGF-β is a
prime candidate for therapeutic targeting. Currently, several therapeutic approaches,
including TGF-β antibodies, antisense oligonucleotides, and receptor kinase inhibitors,
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are being evaluated for cancer treatment. However, because TGF-β is involved in the
maintenance of many normal physiological processes, all current strategies face the
fact that blocking TGF-β signaling might have adverse off-target effects. In fact,
because of the anti-proliferative effect that TGF- has on pre-malignant cells, anti-TGF1 blocking antibodies has been shown to stimulate the growth of preneoplastic
lesions372. Subsequently, in one phase 1 clinical trial that evaluated anti- TGF-
therapeutic potential in melanoma patients, the development of squamous cell
carcinomas was observed373. Thus, the development of therapies that can target TGF-
in the TME specifically is of utmost importance.

CHAPTER II: MATERIAL AND METHODS
Cell Culture
Complete RPMI used for suspension cell cultures was prepared with RPMI-1640
(HyClone, Logan, UT) and supplemented with 10% fetal calf serum (Gemini
Bioproducts, West Sacramento, CA), essential amino acids (Corning, Corning, NY),
non-essential amino acids (Gibco, Waltham, MA), 1mM sodium pyruvate (Corning,
Corning, NY), 50mM 2ME (Fisher Scientific, Waltham, MA), and 0.1M Hepes (Corning,
Corning, NY) and Penicillin/Streptomycin (HyClone, Logan, UT). Adherent cells were
maintained in DMEM supplemented with 10% FCS (Gemini Bioproducts, West
Sacramento, CA) and Penicillin/Streptomycin (HyClone, Logan, UT). All cells were
maintained with 5% CO2 at 37C.
Human lymphocytes were obtained from adult or cord blood. Adult peripheral
blood mononuclear cells (PBMCs), a kind gift from Dr. Michael Nishimura, were
purchased from Key Biologics (Memphis, TN) or Zen Bio (Research Triangle Park, NC)
and came from de-identified adult healthy donors. Cord blood mononuclear cells were
isolated from whole umbilical cord blood kindly donated from Loyola University Medical
center from healthy donors (exclusion criteria: 1. autoimmunity; 2. malignancy; 3. use of
immunosuppressive medication; 4. hyper or hypothyroidism). Heparinized blood was
separated using Lymphopure density gradient medium (Biolegend, San Diego, CA)
according to the manufacturer’s instructions. Whole PBMCs were seeded at 1-2x10^6
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cells per well in 48-well plates in the presence of 200ng/ml soluble anti-CD3 (OKT3
clone, Biolegend, San Diego, CA) and 10ng/ml IL-2 (Peprotech, Rocky Hill, NJ). For
conditions extending past 3 days, cells were split 1:2 and fresh media supplemented
with 10ng/ml IL-2 was added back.
Simian virus 40 large T antigen transfected Jurkat cells, a kind gift from Dr. Art
Weiss (UCSF, San Francisco, CA), were maintained in complete RPMI, and were used
for all transfection experiments.
MEL624 (ATCC, Manassas, VA) were maintained in DMEM (HyClone|Cytiva,
Logan, UT) supplemented with 10% FCS and 10% Penicillin/Streptomycin.
T Cell Isolation and Culture
CD3+, naïve CD4+ and naïve CD8+ T cells were isolated from mononuclear cells
from healthy adult or cord blood via negative selection using the MojoSort CD3+, naïve
CD4+ or naive CD8+ T cell enrichment kit (Biolegend, San Diego, CA). Cell purity for all
enrichments ranged between 90-98%. In all assays using enriched cells, cells were
cultured at 0.5-1x10^6 cells/ml in plates coated with anti-CD3 (OKT3, 5ug/ml) and antiCD28 (5ug/ml) and complete RPMI media supplemented with 10ng/ml IL2.
Flow Cytometry
Antibodies used for the flow cytometry analysis were anti-CD4, -CD8, -Siglec 5
(1A5), -Siglec-3, -Siglec-7, -Siglec-9, -Siglec-10, -CD137, -PD-1, -CD69, -Granzyme B, CD25, -OX40, -ICOS, -CTLA-4, -IFN-, -TNF-, -IL-2, -CD107a, -CD14, -CD36
(Biolegend, San Diego, CA), or in lab prepared phage particles or recombinant Fc
fusion proteins. Cells were blocked with human Fc receptor blocking solution (Human
TruStain FcX, Biolegend) for 10 minutes on ice. For detection of cell surface markers,
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cells were stained with antibody cocktail for 30 minutes at 4C. Intracellular markers
were analyzed after fixing and perming with 4% paraformaldehyde and permeabilization
buffer (50mM NaCl, 0.02% NaN3, 5mM EDTA, 0.5% TritonX, pH7.5), respectively. Data
was collected using BD FACSCanto or BD LSRFortessa and analyzed using FlowJo
v.10 software.
Western Blot and Immunoprecipitation Analysis
For Western blot analysis, cells were lysed in non-reducing SDS sample buffer
(2% SDS, 0.05% bromophenol blue, 62.5mM Tris-HCl, pH 6.8, 10% glycerol, 10mM
Iodoacetamide (IAM)) and boiled 2 x 5min. Equal amount of proteins, based on cell
number, was loaded and separated on SDS-PAGE gel. PVDF membrane transferred
proteins were probed with antibodies against anti-Siglec 5/14 (clone 1A5, Biolegend,
San Diego, CA).
For immunoprecipitation of Siglec-5, cord blood mononuclear cells were
stimulated using soluble anti-CD3 (200ng/ml) and IL2 (10ng/ml) for 2-3 days. 5060x10^6 cells were lysed in 1ml of lysing buffer containing 0.5% NP-40, 0.15M NaCl,
5mM EDTA, and protease and phosphatase inhibitors. The cell lysates were precleared with Protein G-Sepharose pre-incubated with mIgG1 isotype antibody for 2hrs
and immunoprecipitated with CNBr-activated Sepharose conjugated with antiSiglec5/14 antibody (clone 1A5) for 2hrs. After washing 3 times with lysis buffer, the
immunoprecipitants were either boiled in 1x SDS buffer (2% SDS, 0.05% bromophenol
blue, 62.5mM Tris-HCl, pH 6.8, 10% glycerol, 125mM DTT) or further subjected to deglycosylation with PNGase-F (NEB, Ipswich, MA) following the manufacturer’s
instructions. De-glycosilated samples were also boiled in reducing SDS buffer. Samples
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were run on SDS-PAGE gel, and proteins transferred on PVDF membrane. Membranes
were probed with antibodies against anti-Siglec5/14 (polyclonal antibody, R&D,
Minneapolis, MN).
Reporter and Expression Constructs
cDNA sequences of Siglec-5 (SinoBiological) and Siglec-14 (IDT, inc.) were
subcloned into a pME vector using PCR based cloning. To generate a truncated
version of Siglec-5 (pME-tSiglec-5) the ITIM and ITSM were excised from the pMESiglec 5 plasmid with the restriction enzymes BbsI/MfeI (NEB, Ipswich, MA) and blunt
ends were generated with DNA Polymerase I, Large (Klenow) Fragment (Thermo
Fisher, Walthman, MA). The blunt ended plasmid was then ligated using T4 DNA
polymerase (Thermo Fisher, Walthman, MA). NFAT-luciferase and AP-1 luciferase
were previously described374. All plasmid DNA was prepared using CsCl purification
method.
Clone 6FN3/WT FN3 – Fc constructs were generated using PCR based
cloning. Sequences were cloned into a pME vector.
Luciferase Assay
Jurkat Tag cells (2x10^6) were transfected using electroporation (0.8uF and
0.260mV) with 10ug of NFAT or AP1 reporter DNA, along with 1ug of cytomegalovirus
promoter-driven expression vector for Renilla luciferase and 30ug of the expression
vectors for pME-Siglec-5 or pME-tSiglec 5. 48hrs post transfection equal number of
cells were plated on anti-CD3 coated wells in 96-well plates. 4hrs post stimulation cells
were harvested, and luciferase activity was measured using a bioluminescent reporter
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assay kit (Promega, Madison, WI) and a luminometer. For each transfection condition,
the relative luciferase activity was adjusted based on Renilla luciferase activity.
B6N::sfGFP and sfGFP Production
The B6N region (aa 1-154) of the Group B Streptococcus -protein was cloned
as a fusion protein with GFP into a pET-15b vector (MilliporeSigma, Burlington, MA).
This gave us the B6N::sfGFP protein.GFP alone was cloned as a control, giving rise to
sfGFP protein. Plasmids were expressed in lysY/Iq E. coli under inducible conditions.
After overnight culture, bacteria were pelleted and lysed by sonication. Cell free
supernatants were run on a Nickel column and eluted fractions were pulled together and
run on FPLC. FPLC fractions were verified by Coomassie, and proteins were
concentrated and stored in 40% glycerol in -80C.
B6N::sfGFP ELISA
Purified B6N::sfGFP or sfGFP were immobilized on Nunc Maxisorp 96-well plate
(Thermo Fisher Scientific, Waltham, MA) for 2 hours at RT. Target coated plates were
washed 3x with PBST (0.005% Tween-20) and then blocked with 3% BSA for 1 hour at
RT. After washing 3x with PBST, recombinant Siglec 5-Fc chimeric protein (Biolegend,
San Diego, CA) was added and incubated for 2hrs at RT, followed by 3x washes and
incubation with anti-human IgG-HRP antibody for 1hrs. After 3xPBST washes, 1-Step
Ultra TMB-ELISA (Thermo Fisher Sciebtific, Waltham, MA) was added and absorbance
was determined at 450nm with a microtiter plate spectrophotometer (BioTech).
T Cell Stimulation with B6N::sfGFP
Naïve CD4+ or naïve CD8+ T cells were cultured with plate bound anti-CD3
(5ug/ml) and anti-CD28 (5ug/ml) stimulation in the presence of IL2 (10ng/ml) for 3 days.
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Cells were than harvested, washed and re-stimulated with plate-bound anti-CD3
(5ug/ml), anti-CD28 (5ug/ml) and B6N::sfGFP or sfGFP (166nM) for additional 3 days.
To reverse the inhibitory effects B6N::sfGFP has during T cell stimulation, equimolar
amount of B6N::sfGFP or sfGFP were pre-incubated with recombinant hIgG1 Fc or
Siglec-5-Fc proteins for 1hr at 4C with rotation. Mixed proteins were than coated on 96
well non-tissue cultured plates along with anti-CD3 and anti-CD28, before adding 3
days stimulated CD4 T cells. Supernatants from 3-day long cultures were collected and
used for cytokine bead array (CBA) analysis for the expression of IL-5, IL-13, IL-2, IL-6,
IL-9, IL-10, IFN-, TNF-, IL-17A, IL-17F, and IL-22 using the LEGENDplex Human Th
Cytokine (Biolegend, San Diego, CA). Cells from 3-day long cultures were used for
evaluating expression of: CD4, CD8, PD-1, CD137, CD69, CD25, Siglec-5 and
Granzyme B.
Evaluation of Putative Siglec-5 Ligand Expression in Cell Lines
Cell lines: MEL624, Jurkat, Raji, THP1, U937, T2, SNU-475, HEK293t, A549
were blocked with human Fc receptor blocking solution (Human TruStain FcX,
Biolegend) for 10 minutes on ice. Cells were than stained with Siglec-5 Fc chimeric
protein pre-incubated with anti-human IgG Fc fluorescent antibody. As a negative
control, cells were stained with anti-human IgG Fc antibody alone.
Human 1383i T Cell Stimulation
Human 1383i T cells are tyrosinase specific and HLA-A2 restricted T cells that
are generated by transduction of activated primary human T cells with the 1383i T Cell
receptor (isolated from tumor infiltrating lymphocytes from a melanoma patient). Cells or
1383i TCR constructs were a generous gift from Dr. Michael Nishimura at Loyola

66
University Chicago. To stimulate the 1383i T cells, T2 (1x10^6 cells/ml) (ATCC,
Manassas, VA) cells were pulsed with tyrosinase peptide 368-376 (YMDGTMSQV)
(10ug/ml) for 2hrs at 37C. T2 pulsed with tyrosinase were than irradiated with 4425cGy
and used for culturing with 1383i T cells at a ratio of 3:1 (1383i T cells : T2). After 2 days
of stimulation, 1383i T cells were harvested and cell activation and expression of Siglec5 were verified. Cells were than used for re-stimulated with MEL624 (ATCC, Manassas,
VA) at 1:1 ratio. Before co-culture, MEL624 was pre-treated with hIgG1-Fc (10ug/ml)
(Biolegend, San Diego, CA) or Siglec-5-Fc chimeric protein (1 or 10ug/ml) for 30mins.
Cell culture was carried in the presence of 1x Monensin and 1x BrefeldinA (Biolegend,
San Diego, CA). At 12hrs post-stimulation, expression of CD107a, IFN-, TNF- and IL2 was evaluated in the CD4 and CD8 compartments of 1383i T cells.
Preparation of Phage Particles
To prepare phage particles displaying clone 6 FN3 (Ph6) or non-selected FN3
(LBR), bacteria were grown in 2XYT media (Thermo Fisher Scientific, Waltham, MA) at
37C with shaking at 250rpm. Once the bacteria reached density of OD 600=0.5,
bacteriophages were rescued by adding M13KO7 helper phage (MOI=10) (NEB,
Ipswich, MA) for 1hr at 37C. Bacteria were than sub-cultured into fresh 2XYT media
supplemented with 50ug/ml carbenicillin and 100ug/ml kanamycin and grown overnight
at 30C with shaking at 250rpm. Phage particles were precipitated from bacterial
supernatants by 6% PEG 800, 300mM NaCL for 1hr at 4C. Phages were pelleted by
spinning down at 12,000rpm for 20mins. Phage were resuspended in phosphate
buffered saline (PBS) and stored at 4C for short term usage.
Labeling Phage Particles
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100 l of PEG-precipitated phages re-suspended in sterile PBS (OD 7-10) were
mixed with 100 l of 0.2mM Sodium Carbonate buffer. 3.3l of 10mM Alexa FluorTM 488
or 594 NHS ester (Molecular Probes, Eugene, OR) was added and the mix was
incubated at RT and in the dark for 1hour with vortexing every 15 min. Phages were
purified from free fluorochrome by two PEG-precipitations and suspended in PBS.
Freshly labeled phages were used for flow cytometry staining at a concentration of
10OD.
TGF- ELISA
Recombinant active TGF-1 was immobilized on Nunc Maxisorp 96-well plates
(Thermo Fisher Scientific, Waltham, MA) for 2 hours at RT. Target coated plates were
washed 3x with PBST (0.005% Tween-20) and were than blocked with 3% BSA for 1
hour at RT. After washing 3xPBST, phage particles (Ph6 or LBR) or recombinant FN3
based Fc fusion proteins were added and incubated for 2hrs at RT, followed by 3x
washes. Phage binding were detected using anti-P8 M13-HRP antibody. Recombinant
proteins were detected using anti-human IgG-HRP antibody. 1-Step Ultra TMB-ELISA
(Thermo Fisher Sciebtific, Waltham, MA) was used to quantify binding by measuring
absorbance at 450nm with a microtiter plate spectrophotometer (BioTech).
6/WTFN3-Fc Protein Production and Labeling
pME-6/WTFN3-Fc constructs were transfected into CHO cells (ATCC,
Manassas, VA), using PEI as a transfection agent. Stably transfected cells were
selected by growing the cells in Puromycin selection media (10mg/ml). For protein
production CHO cells were cultured in DMEM prepared with 10% FCS previously
stripped from immunoglobulins by running FCS on a protein G column. 1x10^6 CHO
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cells were plated in 30ml media in a T175 flask (Thermo Fisher, Hampton, NH) and
grown for 7 days. Cell culture supernatants were collected and filtered using 0.45uM
filters. Proteins were purified using pre-packed protein G column (GE Healthcare,
Chicago, IL). Fc based proteins were labeled using a One-Step Antibody Biotinylation
Kit (Miltenyi, Beeergisch Gladback, Germany). Biotinylation, as well as specificity of
6FN3-Fc for TGF- was verified using an ELISA by detecting 6FN3-Fc binding to TGF-
with Streptavidin-HRP.

CHAPTER III: RESULTS
Section I
Characterization of the Siglec-5 Receptor in T cells
CD33rSiglec Expression in T cells
CD33rSiglecs are expressed mainly on immune cells. Most human and mouse
immune cells express at least one type of Siglec, with others expressing multiple.
Because each Siglec shows specificity for a unique pattern on sialyation, it is likely that
each receptor has a unique function. Little to no expression has been reported for
resting T lymphocytes of healthy humans, an exception being Siglec-7 and -9, which
can be found in small populations of CD8+ T cells and mediate direct inhibition of TCR
signaling277,285. However, in some pathologies such as cancer or chronic viral infections,
Siglec expression in the T cell compartment can be altered. For example, HIV-infected
patients have a greater proportion of circulating CD4+ T cells expressing the inhibitory
receptors Siglec-5 and Siglec-9, than uninfected healthy donors. Furthermore,
expression of the inhibitory Siglecs correlates with resistance to excessive immune
activation and subsequent HIV-induced cell death274. Similarly, it has been reported that
tumor infiltrating lymphocytes from melanoma patients have high expression of Siglec-9,
which negatively correlates with the prognosis and survival of patients273.
Because both cancers and chronic viral infections provide constant T cell
stimulation, we hypothesized that Siglecs expression might be dependent on the
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activation state of the T cell. Using T cells from healthy adult donors we performed a
screen for Siglec receptor expression (Siglec-3, -5, -7, -8, -9 and -10) in resting versus
stimulated cells (up to 7 days of stimulation). As a positive control for the staining, we
confirmed the expression of each Siglec in Monocytes (size gated and CD4low) from
unstimulated adult PBMCs (Figure 1C). Looking into CD4 (Figure 1A) and CD8 (Figure
1B) T cells specifically, we observed minimal levels of expression for Siglec-6, -8, -9,
and -10. Low levels of expression of Siglec-3 were detected in both CD4 and CD8, but
Siglec-3 expression was not associated with the activation state of the T cells. As
previously reported, we observed that a small population of CD8 T cells expresses
Siglec-7, but the expression was also not associated with the activation state of the T
cells. Unexpectedly, only one of the Siglecs, Siglec-5, had a unique, and activation
associated pattern of expression.

Figure 1: CD33rSiglec Expression in Resting and Activated T cells. Adult PBMCs
were subjected to in vitro activation using soluble anti-CD3 (200ng/ml) and IL-2
(10ng/ml) for up to 7 days. Cells were split every 2-3 days. Expression of Siglecs-3, -5, 6, -7, -8, -9 and -10 was evaluated in A) CD4 and B) CD8 T cells at each time point. C)
Monocyte expression of Siglecs-3, -5, -6, -7, -8, -9 and -10. Experimental donors n=3.
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Siglec-5 Expression in T cells
Surface expression of Siglec-5 begins at 48 hours post-activation in both adult
and cord blood T cells. In adult T cells, Siglec-5 expression peaks at 72hrs postactivation, upon which, it begins to decrease gradually and is entirely lost by day 7 postactivation (Figure 2A and 2B). In cord blood T cells however, surface expression of
Siglec-5 peaks at 48hrs post stimulation, and then begins to decrease gradually (Figure
2C and 2D). Due to convenient availability of cord blood, most further experiments were
performed using cord blood T cells.

Figure 2: Siglec-5 Kinetics of Expression. A) Representative plot and B) summary
for multiple donors of Siglec-5 expression within CD4 and CD8 from adult PBMCs
subjected to in vitro stimulation using soluble anti-CD3 and IL2 for up to 7 days. C)
Representative plot and D) summary for multiple donors of Siglec-5 expression within
CD4 and CD8 from Cord blood mononuclear cells subjected to in vitro stimulation using
soluble anti-CD3 and IL2 for up to 7 days.
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Interestingly, even though the surface expression of Siglec-5 does not appear
until 48hrs post-stimulation (Figure 2), using Western blotting we can detect Siglec-5
protein as early as 24hrs post-stimulation (Figure 3). This data suggests a regulatory
mechanism between translation and trafficking of the protein to the cell surface.

Figure 3: Siglec-5 Expression Analysis in T cells Using Western Blot. CD3+ T cells
enriched from adult PBMCs were cultured with plate-bound anti-CD3 and anti-CD28
stimulation with IL-2 for 0, 1, 2, 3. At each time point cell lysates were prepared using
denaturing, non-reducing conditions (Representative blot of 3 donors).
mRNA studies of Siglec-5 showed a basal level of expression even in resting T
cells, though the levels peak at 24hrs post-stimulation (Figure 4).
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Figure 4: Siglec-5 mRNA Expression in T cells. CD3+ T cells were enriched from
adult PBMCs and cultured with plate-bound anti-CD3 and anti-CD28 stimulation with IL2 for 0, 1, 2, 3 or 4 days. mRNA was prepared from each time point and Siglec-5 mRNA
was detected using qPCR.
Within its extracellular and ligand-binding domain Siglec-5 shares high sequence
homology with its paired receptor Siglec-14. Because most commercially available
antibodies recognize Siglec-5 within its extracellular domain, we cannot rely on this
method of detection of the protein to claim Siglec-5 expression. Instead, a distinction or
co-expression with Siglec-14 must be confirmed by Western blot analysis because of
the distinct molecular weights the two receptors have. Using Western blot analysis of
immunoprecipitated proteins, we sought to determine whether activated T cells express
Siglec-5, Siglec-14, or both. If the protein observed by flow cytometry is Siglec-5, we
expect to see a band of 68kDa, versus a band of 42kDa for Siglec-14. Compared to
Jurkat T cells overexpressing Siglec-5 or Siglec-14 cDNA, we observed that T cells
express Siglec-5, with minimal to no expression of Siglec-14 (Figure 5A). However, the
bands we observed for Siglec-5 in this immunoprecipitation assay did not match the
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predicted 68kDa. Because Siglec-5 has at least 8 described N-based glycosylation
sites, we hypothesized that removal of the core glycosylation will give us a more
accurate assessment of which protein, Siglec-5, or Siglec-14, is expressed in activated
T cells. Using PNGase F treatment of Immunoprecipitated proteins, we removed all Nlinked glycosylation and observed that the IP-ed protein samples from activated T cells
correspond to Siglec-5. Minimal expression of Siglec-14 was observed (Figure 5B).
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Figure 5: Immunoprecipitation of Siglec-5 from T cells. Cord blood T cells were
stimulated with soluble anti-CD3 and IL2 for 2 days. Cells were lysed using mild
detergent (0.5% NP-40) and pre-cleared with Protein G-Sepharose pre-incubated with
mIgG1 isotype antibody. Proteins were immunoprecipitated by incubating with antiSiglec-5/14 mAb (clone 1A5) or mIgG1 isotype CNBr conjugated beads. Where
indicated, immunoprecipitated proteins were treated with PNGase F to remove N-linked
glycosylations. As controls, Jurkat T cells were transfected with Siglec-5, Siglec-14 or
an empty vector and whole-cell lysates were prepared. All samples were run on SDSPAGE and transferred to PVDF membranes. Membranes were blotted with antiSiglec5/14 polyclonal antibodies.
Siglec-5 Follows Expression Kinetics of Co-inhibitory and Co-stimulatory
Checkpoint Receptors in T cells
Checkpoint receptors, co-stimulatory and co-inhibitory, play a crucial role in finetuning the fate of T cell activation, proliferation, and differentiation. These receptors are
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expressed only upon T cell activation and the balance between stimulating and
inhibitory receptors drives T cells into distinct functional states. Co-stimulating
receptors, such as OX-40, ICOS, 4-1BB synergize with TCR signaling and help T cells
develop an effective functional response. On the other hand, co-inhibitory checkpoints,
such as PD-1 and CTLA-4, antagonize TCR signaling and suppress T cell activation,
thus preventing excessive inflammatory responses and the development of autoimmune
diseases. Specific activation of checkpoint receptors depends on the availability of their
distinct ligands, which provides another level of regulation of their activity.
Because Siglec-5 has activation associated pattern of expression (Figure 2), we
asked if it follows the expression kinetics of other, well-described checkpoint receptors.
Comparing Siglec-5 expression with co-stimulatory checkpoint receptors, we observe a
close to overlapping expression pattern with OX-40 (Figure 6B). In the case of ICOS
(Figure 6A) and 4-1BB (Figure 6C), we see that T cells upregulate these molecules at
day 1 post-stimulation versus day 2 post-stimulation for Siglec-5. 4-1BB is
predominantly expressed by activated CD8 T cells and not CD4 T cells. On the other
hand, Siglec-5 almost completely overlaps the expression kinetics of the co-inhibitory
checkpoint receptor PD-1 (Figure 7A). Siglec-5 kinetics of expression closely resembles
CTLA-4 expression too, but CTLA-4 precedes and first appears at day 1 poststimulation (Figure 7B). Altogether, these data show that Siglec-5 follows the expression
kinetics of other checkpoint receptors in T cells.
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Figure 6: Expression Kinetics of Siglec-5 and Stimulatory Checkpoint Receptors
OX-40, ICOS and 4-1BB in T cells. Cord blood mononuclear cells were stimulated with
soluble anti-CD3 (0.2ug/ml) and IL2 (10ng/ml) for up to 7 days. Cells were split every 23 days. At each time point, cells were stained and analyzed for expression of Siglec-5
and A) OX40, B) ICOS or C) 41BB within the CD4 or CD8 T cell compartments. Data is
a summary for n=3 individual donors.
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Figure 7: Expression Kinetics of Siglec-5 and Inhibitory Checkpoint Receptors
PD-1 and CTLA-4 in T cells. Cord blood mononuclear cells were stimulated with
soluble anti-CD3 (0.2ug/ml) and IL2 (10ng/ml) for up to 7 days. Cells were split every 23 days. At each time point, cells were stained and analyzed for expression of Siglec-5
and A) PD1 or B) CTLA-4 within the CD4 or CD8 T cell compartments. Data is a
summary for n=3 individual donors.
The Function of Siglec-5 in T cells
Studies evaluating Siglec-5 expression in innate immune cells such as
monocytes and neutrophils show that Siglec-5 is an inhibitory receptor that mediates its
function through the recruitment of Shp1 and Shp2 phosphatases to the ITIM and ITSM
motifs. These phosphatases de-phosphorylate molecules involved in signaling
cascades and thus suppress immune cell activation286. Furthermore, having observed
that Siglec-5 follows the expression kinetics of the well-known inhibitory checkpoint PD1 (Figure 7A) we looked at whether the two receptors share any other features. Even
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though PD-1 belongs to the CD28 family of receptors, its cytoplasmic domain is more
like the CD33rSiglec family. When we compared the cytoplasmic and thus signaling
domain of PD-1 and Siglec-5, we saw that they both have the inhibitory ITIM and ITSM
(Figure 8) which they use to mediate inhibitory functions.

Figure 8: Similarity within the Cytoplasmic Tail of Siglec-5 and PD-1. The
cytoplasmic sequence of Siglec-5 was compared to the cytoplasmic sequence of PD-1.
Shared protein motifs are highlighted in red, and conserved amino acids are highlighted
in blue.
Based on our knowledge about Siglec-5 from innate immune cells and its
similarity with PD-1, we hypothesized that Siglec-5 is a negative regulator of T cell
activation. To test this hypothesis, we used an overexpression system. We cotransfected Siglec-5 expression vector with reporter vectors for NFAT and AP-1 and
measured the luciferase activity. If Siglec-5 is an inhibitory receptor, we expect to see
reduced NFAT and AP-1 activity. Compared to control cells, overexpression of Siglec-5
leads to a significant reduction in NFAT and AP-1 activity upon anti-CD3 stimulation
(Figure 9).

80

Figure 9. The Function of Siglec-5 in T cells. Jurkat T ag cells were transiently
transfected with empty or Siglec-5 expression vector, along with NFAT and AP-1
luciferase reporter vectors. 4hrs post anti-CD3 stimulation, A) NFAT and B) AP-1
luciferase activity was measure. Relative luciferase activity was calculated based on
Renilla luciferase activity. Statistical analysis: 2wayANOVA, Tukey’s multiple
comparison test, *** p<0.001, **** p<0.0001. Representative figures from 3 separate
experiments, each performed in triplicate.
To understand how Siglec-5 blocks T cell activation, we tested if the ITIM and
ITSM are required. For this, we mutated the Siglec-5 receptor such that we generated a
cytoplasmic truncation by excising both the ITIM and ITSM. If ITIM and ITSM are the
only domains of Siglec-5 responsible for its inhibitory effects in T cells, we expected to
see complete restoration of NFAT and AP1 activity. However, we only observed partial
restoration for both reporters (Figure 10).
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Figure 10: ITIM and ITSM are Partially Required for Siglec-5 Mediated Inhibition of
T cells: Jurkat T ag cells were transiently transfected with empty, full-length Siglec-5, or
a truncated Siglec-5 (tSiglec5) lacking both the ITIM and ITSM motifs. 4hrs post-antiCD3 stimulation, A) NFAT and B) AP-1 luciferase activity was measure. Relative
luciferase activity was calculated based on Renilla luciferase activity. Statistical
analysis: 2way ANOVA, Tukey’s multiple comparisons test, ** p<0.01, *** p<0.001, ****
p<0.0001. Representative figures from 3 separate experiments, each performed in
triplicate.
-protein Mediated Regulation of T cell Activation
Pathogens have evolved to evade the immune responses by utilizing
immunomodulatory mechanisms that generally serve to keep immune cells from overactivation. Group B Streptococcus (GBS), a major pathogen of newborns, expresses a
surface protein, -protein, that suppresses different arms of the immune response,
including binding and activating the Siglec-5 receptor in innate immune cells. More
specifically, it was narrowed down that the B6N domain (aa1-152) of the -protein was
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responsible for engaging and activating the Siglec-5 receptor. -protein/Siglec-5
interactions result in inhibition of phagocytosis and suppression of proinflammatory
cytokine production by neutrophils and monocytes in response to GBS281,282. Using the
B6N region of the -protein, we asked whether engaging Siglec-5 with a specific ligand
will affect the activation of primary T cells. From our overexpression studies (Figure 9)
we know that Siglec-5 is an inhibitory receptor in T cells, and now we hypothesized that
direct activation of Siglec-5 with B6N will suppress T cell activation. To begin testing our
hypothesis, we first generated the B6N protein as a fusion with GFP (B6N::sfGFP). As a
control, we expressed GFP alone (sfGFP). Using an indirect ELISA system where
B6N::sfGFP and sfGFP were immobilized on the plate, we verified Siglec-5 specificity
for B6N::sfGFP, but not sfGFP, using a recombinant Siglec-5-Fc chimeric protein for
detection (Figure 11).
Siglec-5 Fc binding
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Figure 11: Siglec-5 Binds B6N::sfGFP, but not sfGFP. B6N::sfGFP and sfGFP were
immobilized on ELISA plates. Unconjugated recombinant Siglec-5-Fc chimeric protein
was used as a detection reagent. HRP-conjugated anti-hIgG was used for the detection
of Siglec-5-Fc binding.
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To test our hypothesis that activation of Siglec-5 with B6N::ssGFP will suppress
T cell activation we set up an assay where naïve CD4 or CD8 T cells were stimulated
for 3 days. From our kinetics studies (Figure 2), at day 3 post-stimulation Siglec-5
expression is high and majority of cells express it. We used the 3 day stimulated T cells
for a re-stimulation assay, using plate-bound anti-CD3, anti-CD28 along with
B6N::sfGFP or sfGFP. We cultured the cells for additional 3 days and then looked at
cytokine production and expression of activation associated molecules. We observed
that CD4 T cells stimulated in the presence of B6N::sfGFP had reduced production of
the proinflammatory cytokines IFN- and IL-22 (Figure 11A). In contrast, we observed
an increase in Th2 associated cytokines such as IL-4, IL-5, IL-13 (Figure 11B).
Furthermore, effector molecules, such as Granzyme B were also significantly reduced in
the presence B6N::sfGFP (Figure 12).
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Figure 12: B6N::sfGFP Suppresses Inflammatory Cytokine Production in CD4 T
cells. Naïve CD4 T cells were cultured with plate-bound anti-CD3 and anti-CD28
stimulation in the presence of IL-2 for 3 days. Cells were then harvested and restimulated with plate-bound anti-CD3, anti-CD28 and B6N::sfGFP or sfGFP.
Supernatants from the 3 days cultures were collected and used for cytokine bead array
analysis. Summary for A) IFNy IL-22 and B) IL-4, IL5 and IL13 levels from multiple
donors. Statistical analysis: Ratio paired two-tailed t-test; * p<0.05; ** p<0.01; ***.
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Figure 13: B6N::sfGFP Decreases Granzyme B Expression in CD4 T cells. Naïve
CD4 T cells were cultured with plate-bound anti-CD3 and anti-CD28 stimulation in the
presence of IL2 for 3 days. Cells were then harvested and re-stimulated with platebound anti-CD3, anti-CD28 and B6N::sfGFP or sfGFP. At day 3 post re-stimulation
intracellular stain for Granzyme B was performed. A) Representative plot and B)
summary for gMFI and frequency for multiple donors. Statistical analysis: Ratio paired
two-tailed t-test; * p<0.05; ** p<0.01.
Following the reduction in function-associated markers, B6N::sfGFP also suppressed
the expression of activation-associated molecules in CD4 T cells, such as CD69,
CD137 and PD1.
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Figure 14: B6N::sfGFP Suppresses Expression of Activation Associated
Molecules in CD4 T cells. Naïve CD4 T cells were cultured with plate-bound anti-CD3
and anti-CD28 stimulation in the presence of IL2 for 3 days. Cells were then harvested
and re-stimulated with plate-bound anti-CD3, anti-CD28 and B6N::sfGFP or sfGFP. On
day 3 post-re-stimulation cells were stained for surface marker expression. A)
Representative plots and B) summary for CD69, PD1 and CD137 expressing cells.
Statistical analysis: Ratio paired two-tailed t-test; * p<0.05; ** p<0.01; *** p<0.001.
In CD8 T cells stimulation in the presence of the B6N protein led to reduced
production of the proinflammatory cytokine IFN- (Figure 15). Like CD4 T cells, B6N
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also caused a reduction in Granzyme B production by CD8 T cells; however, no
significance was reached (Figure 16). Activation markers, such as CD137 and PD-1, but
not CD69 were also significantly reduced in CD8 T cells stimulated in the presence of
the B6N protein (Figure 17).

Figure 15: B6N::sfGFP Suppresses Inflammatory Cytokine Production in CD8 T
cells. Naïve CD8 T cells were cultured with plate bound anti-CD3 and anti-CD28
stimulation in the presence of IL-2 for 3 days. Cells were than harvested and restimulated with plate bound anti-CD3, anti-CD28 and B6N::sfGFP or sfGFP.
Supernatants from the 3 days cultures were collected and used for cytokine bead array
analysis. Statistical analysis: Ratio paired two-tailed t-test; *, p<0.05
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Figure 16: B6N::sfGFP Reduces Granzyme B Expression in CD8 T cells. Naïve
CD8 T cells were cultured with plate-bound anti-CD3 and anti-CD28 stimulation in the
presence of IL2 for 3 days. Cells were then harvested and re-stimulated with platebound anti-CD3, anti-CD28 and B6N::sfGFP or sfGFP. On day 3 post-re-stimulation
intracellular stain for GranzymeB was performed. A) Representative plot and B)
summary for gMFI and frequency for multiple donors. Statistical analysis: Ratio paired
two-tailed t-test; ns, p>0.05
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Figure 17: B6N::sfGFP Reduces Expression of Activation Associated Molecules
in CD8 T cells. Naïve CD8 T cells were cultured with plate-bound anti-CD3 and antiCD28 stimulation in the presence of IL2 for 3 days. Cells were then harvested and restimulated with plate-bound anti-CD3, anti-CD28 and B6N::sfGFP or sfGFP. At day 3
post re-stimulation cells were stained for surface marker expression. Data summary for
CD69, PD1 and CD137 expressing cells in multiple donors. Statistical analysis: Ratio
paired two-tailed t-test; ns, p>0.05, * p<0.05
-protein Mediates Inhibition of T cell Activation via Engagement of Siglec-5
From the literature, as well as our ELISA data (Figure 11), we know that Siglec-5 binds
to B6N region of the -protein. However, whether in our assay B6N engages Siglec-5 to
mediate its inhibitory effects is unclear (Figures 12-17). To understand this, we set up
an assay where we pre-incubated B6N with soluble Siglec-5 Fc chimeric protein before
coating it on plates, along with anti-CD3 and anti-CD28. We hypothesize that during the
pre-incubation the Siglec-5 Fc will bind to B6N, and thus when coated onto plates B6N
will no longer be available for binding to the endogenous Siglec-5 receptor on T cell.
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Using this setting, we observed that B6N did not suppress the activation of T cells, as
measured by the level of expression of the effector molecule Granzyme B (Figure 18).
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Figure 18: Limiting the Availability of B6N::sfGFP by Pre-incubation with Soluble
Siglec-5 Protein, Rescues the Expression of Granzyme B in CD4 T cells. Naïve
CD4 T cells were cultured with plate-bound anti-CD3 and anti-CD28 stimulation in the
presence of IL-2 for 3 days. Cells were then harvested and re-stimulated with plate
bound anti-CD3, anti-CD28 and B6N::sfGFP or sfGFP pre-incubated with hIgG1 Fc or
Siglec-5 Fc at equimolar ratios. On day 3 post-re-stimulation intracellular stain for
Granzyme B was performed. Data represents a summary for fold change in gMFI for
multiple donors. Statistical analysis: one-way ANOVA, Tukey’s multiple comparisons
test, ns p>0.05, ** p<0.01.
Siglec-5 Engagement Suppresses the T cell-specific Anti-tumor Response in vitro
The data so far suggest that Siglec-5 is a checkpoint-like receptor that inhibits T
cell activation. Considering the immunosuppressive functions that inhibitory checkpoint
receptors, such as PD-1 and CTLA-4, play in regulating the anti-tumor T cell response,
we asked if Siglec-5 provides a a mechanism by which cancers mediate T cell immune
suppression. Siglec-5 ligands are generally sialic acids attached to glycoproteins and
glycolipids. While we know the exact patterns of sialyation that Siglec-5 prefers, the
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underlying proteins or lipids are poorly characterized. To obtain a broad idea if cancer
cells express any putative ligands for Siglec-5, we stained different human cancer cell
lines with a recombinant Siglec-5-Fc chimera protein. We found that several of the
tested cell lines have varying levels of Siglec-5 binding, suggesting the presence of
putative ligands expressed by the cancer cell lines (Figure 19).

Figure 19: Putative Siglec-5 Ligands are Expressed by Cancer Cell Lines. A)
Representative plots of human cancer cell lines stained with recombinant Siglec-5 Fc
chimeric protein and anti-human IgG1 Fc fluorescent antibody. B) Summary of multiple
staining.
Because cancer cells express putative ligands, we hypothesized that Siglec-5 is
a mechanism by which cancers evade the anti-tumor T cell response. To test this
hypothesis, we used adult T cells transduced with a TCR (1383i TCR) specific for the
melanoma antigen tyrosinase (TCR constructs, or 1383i TCR T cells provided by Dr.
Michael Nishimura’s lab). We first tested and confirmed that the 1383i TCR T cells
stimulated in an antigen-specific manner also follow the expression kinetics of Siglec-5
like primary T cells. In other words, resting 1383i TCR T cells have low Siglec-5
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expression. Upon stimulation with T2 cells pulsed with tyrosinase peptide we see
activation-dependent increase of Siglec-5 (Figure 20).
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Figure 20: Tyrosinase Specific T cells Upregulate Expression of Siglec-5 After
Stimulation. Adult T cells were transduced with the 1383i TCR specific for the
melanoma antigen tyrosinase. Transduced T cells were enriched using the CD34t
selection marker, which is expressed in-frame with the tyrosinase specific 1383i TCR
and denotes 1:1 expression ratio. 1383i TCR T cells were then stimulated with a 1:3
ratio of T cells to irradiated T2 pulsed with tyrosinase, and cultured for 0, 1, 2, 3, 4, and
5 days. Siglec-5 expression within the CD4 and CD8 compartment was evaluated at
each time point.
We established an assay where 1383i TCR T cells were stimulated in an antigenspecific manner for 2 days. When the expression of Siglec-5 is high, we re-stimulated
the 1383i TCR T cells with the MEL624 cancer cell line, which carries putative Siglec-5
ligands, in the presence of recombinant Siglec-5 Fc chimeric protein. We hypothesize
that the Siglec-5 Fc will bind and limit the availability of the putative Siglec-5 ligands
expressed by MEL624 and in that way will disrupt the activation of SIglec-5 signaling in
the T cells. Because Siglec-5 signaling blocks T cell activation, we expect that
disrupting the Siglec-5 signaling axis will reinvigorate the T cell-specific anti-tumor
response. A marker of functionality of T cells is their ability to produce cytokines and
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release cytotoxic granules. The higher the frequency of such cells, the stronger the
response is. In a dose dependent manner, Siglec-5 Fc treatment led to increase in the
frequency of IFN-, TNF-, IL-2 (Figure 21) and CD107a (Figure 22) producing CD4 T
cells.

Figure 21: Disrupting the Sigle-5 Signaling Axis Re-invigorates T cell Specific
Cytokine Production in Response to Cancer Cells. 1383i T cells were stimulated
with T2 pulsed with tyrosinase peptide. 2 days post-stimulation, Siglec-5 expression
was verified, and cells were used for stimulation with the Siglec-5 ligand carrying
MEL624 cancer cell line in the presence of Siglec-5-Fc or control hIgG1-Fc protein. The
assay was carried in the presence of Brefeldin A and Monensin. A) Representative plots
and B) summary of multiple donors of frequency of CD4 T cells expressing IFN-, TNF and IL-2 at 12hrs post-stimulation. Statistical analysis: Ratio paired two-tailed t-test; *,
p<0.05
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Figure 22. Disrupting the Siglec-5 Signaling Axis Re-invigorates T cell Expression
of the Cytotoxic Marker CD107a. 1383i T cells were stimulated with T2 pulsed with
tyrosinase peptide. 2 days post-stimulation, Siglec-5 expression was verified, and cells
were used for stimulation with the Siglec-5 ligand carrying MEL624 cancer cell line in
the presence of Siglec-5-Fc or control hIgG1-Fc protein. Assay was carried in the
presence of BrefeldinA and Monensin. A) Representative plots and B) summary of
multiple donors of frequency of CD4 T cells expressing CD107a. Statistical analysis:
Ratio paired two-tailed t-test; *, p<0.05
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Section II
Development of Novel Tools to Identify TGF-β Producing Cells
Development and Identification of Active TGF-β Specific Reagent
To develop a reagent selective for active TGF-β, a previous member of our lab,
Veronica Volgina, PhD, generated a fibronectin type III (FN3) domain-based phage
display library by mutating the BC, DE, and FG loops within the FN3. Phage display
technology is a powerful in vitro technique for the development of high affinity reagents.
The three loops within the FN3 domain structurally resemble the immunoglobulin
complementary determining regions and serve as sites for diversification and target
recognition. The library of proteins displayed onto coat protein III of M13 bacteriophages
was used for several selection rounds. First, clones specific for latency-associated
protein (LAP) were removed using positive selection with LAP-coated beads. Next,
negatively selected phages were screened for binding to active TGF-β (Ala 279-Ser290)
coated beads. Out of the 400 clones screened, 16 clones bound to TGF-β with minimal
cross-reactivity to LAP (Figure 23A). Because of its highest binding affinity, the phage
clone 6 (Ph6) was used for further characterization.
Ph6 was next shown to not only bind but also neutralize TGF-β biological effects.
Looking at phosphorylated SMAD2/3 as a readout for TGF-β signaling, it was shown
that Ph6 blocks SMAD2/3 phosphorylation in Jurkats treated with TGF-β (Figure 23B).
Furthermore, it was also shown that Ph6 blocks epithelium to mesenchymal transition
(EMT), a well-described process upon treatment of NMuMG cells with TGF-β. Blockade
of EMT in this assay was assessed by measuring the levels of E-cadherin, a marker of
epithelial, but not mesenchymal cells (Figure 23C).
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Figure 23: Development and Characterization of an Affinity Reagent Specific for
Active TGF-β. A) Phage clones binding to active TGF-β -b or LAP evaluated via ELISA.
The detection reagent used for detecting phage is an anti-P8 phage protein antibody. Xaxis denotes each clone tested. B) Jurkat T cells were incubated overnight with TGF-β
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(10ng/ml) preincubated with Ph6 or unselected library (LBR). Phosphorylation of
SMAD2/3 was assessed by flow cytometry. C) NMuMG cells were stimulated for 48hrs
with TGF-β (10ng/ml) or TGF-β pre-incubated with 1 OD concentration of phage clones
6, 24 or LBR. Cells were analyzed by Western blot for expression levels of E-Cadherin,
a marker of epithelial, but not mesenchymal cells (Data generated by Veronica Volgina,
PhD)
Detection of Membrane-bound TGF- uUsing Ph6
Although several anti- TGF- antibodies are commercially available, detecting of cell
surface-bound active TGF- remains challenging. To develop an alternative approach,
we tested if phage clones 6 (Ph6) can be used to detect active TGF-  via flow
cytometry. We prepared phages and verified Ph6 specificity for TGF-β via ELISA
(Figure 24). We then labeled the phages with Alexa Fluor 488 or 594 NHS ester
(Molecular Probe) and used them for staining cells for flow cytometry analysis.
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Figure 24: Verification of Ph6 Binding to TGF-β via ELISA. Phage particles were
precipitated from bacterial supernatants (bacteria grown overnight) by 6% PEG 800,
300mM NaCl for 1hr at 4C. Phages were pelleted by spinning down at 12,000rpm for
20mins. Isolated phages at ssDNA OD = 9 were used for testing their ability to bind
TGF-β via ELISA. Phages were detected using an anti-P8 M13-HRP antibody.

98
Our lab has shown that monocytes provide TGF-β to naïve CD4 T cells for
regulatory T cell induction in a cell-contact dependent manner. This suggests that
monocytes carry active TGF-β on their surface375. We hypothesized that if monocytes
provide active TGF-β to naïve T cells, then we will detect active TGF-β on monocyte
surfaces. Using human umbilical cord blood mononuclear cells, we found that a
subpopulation of CD14+CD36hi monocytes expresses active TGF-β (Figure 25).
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Figure 25: Surface Expression of Active TGF-β on Human CD14+CD36+
Monocytes. Flow cytometry analysis of human monocytes stained with Ph6 or LBR
directly conjugated to Alexa Fluorochromes. Mononuclear cells were isolated from
human umbilical cord blood and stained with antibodies against CD14 and CD36, in
addition to phage particles, LBR or Ph6, labeled with AF488 or A594. Cells were stained
for 1 h at +4C and then analyzed using flow cytometry A) Representative plots and B)
summary of CD36+TGF-β+ within CD14+ monocytes.
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Generation of Recombinant Clone 6 FN3 Based Proteins
Monobodies displayed on the phage surface can be used as affinity reagents,
however, a soluble form of the antigen-binding protein might be more robust for in vitro
and in vivo applications. We generated a soluble protein by using a mammalian
expression system consisting of the FN3 domain fused to the constant regions (CH2
and CH3) of human IgG1, separated by the hinge region. (Figure 26). The construct
was trasnfected into CHO cell line. Upon establishment of a stably producing cell line
using drug selection, cells were grown and suppernatants were collected for protein
purification using a protein G column.

Figure 26: Schematic of 6/WT FN3-Fc Chimeric Protein. Clone 6 or WT FN3 was
cloned as a fusion with CH2 and CH3 domains of human IgG1. The hinge region of
human IgG1 was used as a spacer between FN3 and Fc regions. The protein was
expressed under the control of a constitutively active SR-a promoter.
Recombinant 6FN3-Fc or control WTFN3-Fc affinity for TGF- was verified using an
ELISA (Figure 27). This data suggest that we have successfully expressed a
recombinant protein specific for active TGF-.
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Figure 27: Verification of 6FN3-Fc Protein Binding for TGF-. 15ng/ml of active
TGF-β was immobilized on ELISA plate and 3.75ug/ml or 0.75ug/ml of 6FN3-Fc or
WTFN3-Fc proteins were used as detection reagents. Anti-human IgG-HRP antibody
was used to detect Fc protein binding to TGF-β.

Detection of Surface Bound TGF-β Using 6FN3-Fc
To use the proteins for analysis of TGF-β expressing cells via flow cytometry, we
biotinylated the 6FN3-Fc protein. Due to poor production yield for WTFN3-Fc, as a
control, we biotinylated a hIgG1 Fc protein. We verified the biotinylation and binding to
TGF-β using ELISA and Streptavidin-HRP as a detection reagent (Figure 28).
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Figure 28: Verification of Biotinylated 6FN3-Fc Protein Binding to TGF-β. 6FN3-Fc
and hIgG1 Fc proteins were biotinylated using a one-step biotinylation kit (Miltenyi
Biotech). Successful biotinylation was confirmed by the ability of 6FN3-Fc to bind to
TGF-β and its detection using Streptavidin-HRP.
However, even though 6FN3-Fc retains its ability to bind TGF-β via ELISA, it did not
bind to live cells, like the Ph6 clone did (Figure 29).

Figure 29: Recombinant 6N3-Fc Protein is not Suitable for Detection of Active
TGF-β Expressed on Cell Surfaces. Mononuclear cells were isolated from human
umbilical cord blood and stained with antibodies against CD14 and CD36, in addition to
biotinylated 6FN3-Fc or hIgG1 Fc proteins.

CHAPTER FOUR: DISCUSSION
Section I
Siglec-5 – a Novel Checkpoint Receptor in T cells
Siglec-5 Expression in T cells is Activation Dependent
To prevent inappropriate immune activation and subsequent immune injuries, the
immune system has evolved strategies to help discriminate self from non-self, or
healthy from altered and infected. These strategies relay on activating different
receptors that recognize molecular patterns specific for self and healthy cells. One such
family of receptors is the CD33rSiglecs, a family of C-type lectins specific for sialic
acids. Sialic acids are derivatives of the sugar neuraminic acid and are attached to the
terminal position of glycoproteins or glycolipids. Because of their convenient location,
sialic acids can easily interact and engage Siglec receptors and thus regulate host
homeostasis. Most Siglecs have inhibitory functions, and their recognition of sialic acids
is one mechanism by which the immune system mediates tolerance towards self. The
interaction of sialic acids with Siglecs can also play a role in increasing the activation
threshold of immune cells, as is the case of Siglec-2 (CD22) in inhibiting B cell receptor
signaling and subsequent prevention of unwanted antibody responses against selfantigens249. However, in some pathologies, such as bacterial and viral infections or
cancer, normal sialyation can be altered in favor of the pathogen or altered cells and
result in an inappropriate immune response.
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Reports from the literature suggest that human T cells have evolutionally lost the
expression of most CD33rSiglecs under healthy conditions270. However, in pathologies
such as cancer or chronic viral infections the expression of some Siglecs is
upregulated274,376. Because both cancer and chronic viral infections provide chronic
antigen stimulation of T cells, we asked if CD33rSiglec expression changes during T cell
activation. We screened activated T cells for Siglecs -3, -5, -6, -7, -8, -9, and -10 and
found that among all, only Siglec-5 had an activation associated pattern of expression.
We detected Siglec-7 expression in small fraction of CD8 T cells, as well as Siglec-3 in
both CD4 and CD8 T cells, but their expression was not associated with activation
(Figure 1). We investigated the kinetics and found that Siglec-5 expression is only
detectable after 48hrs of stimulation, a unique trait for most checkpoint receptors which
expression is upregulated only after T cell activation (Figure 2). Interestingly, in adult T
cells, the peak expression of Siglec-5 was at 72hrs post-stimulation (Figure 2A and 2B),
but in perinatal T cells (from cord blood) the peak was at 48hrs (Figure 2C and 2D).
Following peak expression in both adult and perinatal T cells, the levels of Siglec-5
gradually decrease and by day 7 post-stimulation the expression is completely lost. The
discrepancy between the peaks of Siglec-5 expression might be coming from the
different ratios of naïve versus antigen-experienced T cells, with perinatal T cells having
higher frequency of naïve T cells than adult. Alternatively, these differences might be
due to intrinsic differences between adult and perinatal T cells377. Using Western
blotting, we can detect Siglec-5 protein expression as early as 24hrs post-stimulation, in
contrast to its surface expression at 48hrs post-stimulation (Figure 3). These data

105
suggest that localization and translocation of Siglec-5 to the surface are tightly
controlled, and distinct signals or mechanisms might be regulating these two processes.
Further studies are needed to elucidate the delay between translation and trafficking of
Siglec-5 to the cell surface.
Siglec-5 and Siglec-14 share high sequence homology within their ligand-binding
domains and are described as paired receptors with opposing functions due to
differences in their intracellular and thus signaling domains 303. While Siglec-14
promotes activation of innate cells such as neutrophils and monocytes, Siglec-5 blocks
it. The balance between Siglec-5 and Siglec-14 signaling is thought to fine-tune the
innate immune response. Even though Siglec-5 and Siglec-14 have unique domains,
most of the commercially available antibodies bind within the shared sequences and
don’t distinguish between the two. To determine whether T cells express both Siglec-5
and Siglec-14, or either one of the two proteins, we performed Western blot analysis on
immunoprecipitated proteins from primary T cells (Figure 5). Our data suggest that the
dominant protein expressed in T cells is Siglec-5. We don’t exclude the possibility that
small amounts of Siglec-14 are also expressed, but further verification is needed. To
confirm the presence of Siglec-14 we could perform mass spectrometry on the
immunoprecipitated proteins. To further strengthen our data that Siglec-5 is the
dominant protein expressed in activated T cells, we also performed mRNA studies to
detect Siglec-5 (Figure 4), but not Siglec-14 mRNA (Data not shown).
Siglec-5 is an Inhibitory Receptor in T cells
Siglec-5 is an inhibitory receptor that blocks the activation of innate immune cells,
such as monocytes, neutrophils, and macrophages. The cytoplasmic tail of Siglec-5
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contains two inhibitory domains, ITIM and ITSM, which are well conserved among other
inhibitory receptors as well. Upon ligand engagement, the ITIM and ITSM of Siglec-5
get phosphorylated and serve as recruitment sites for phosphatases such as Shp1 and
Shp2281,282. These phosphatases de-phosphorylate proteins involved in signaling
cascades that activate immune cells and, in that way, prevent the activation of the
immune cell. For example, it has been reported that Siglecs impair the function of other
activating receptors, such as TLRs, in innate immune cells. Siglec-5 and Siglec-9 in
particular bind most strongly and cross-react with all TLR receptors. Siglecs bind to
TLRs in a sialic acid-dependent manner and mediate dampening of the TLR-dependent
activation of the immune cell in response to pattern- or danger-associated molecular
patterns (PAMPs or DAMPs) via the recruitment of the Shp phosphatases. Upon
activation TLR4 for example can upregulated the expression and surface localization of
neuraminidase, Neu1, that cleave the sialic acids and disrupt the Siglec binding.
Subsequently the Siglec mediated restrain of TLR4 activation can be released 378,379.
Biochemically, Siglec-5 mediates its inhibitory signaling using the exact inhibitory
domains, ITIM and ITSM, that the well-known checkpoint PD-1 does. PD-1 is a wellcharacterized inhibitory receptor that mediates suppression of T cell activation. PD-1
engagement with its ligands PD-L1 and PD-L2 results in phosphorylation of the tyrosine
residues within the ITIM and ITSM domains of its cytoplasmic tail. The phosphorylated
tyrosine residues then recruit Shp1/2 phosphatases. Shp1/2 mediate T cell inhibition by
reducing the phosphorylation of TCR/ZAP70 and downstream PKC- signaling231,234,
as well as PI3K/Akt signaling following CD28 activation221. Altogether, these leads to
decrease in T cell proliferation, cytokine production and cytolysis.
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Based on its similarity with PD-1 (Figure 8), as well as what we know about it
from innate immune cells, we hypothesized that the function of Siglec-5 is to inhibit T
cell activation. To test this hypothesis, we used an over-expression system where we
co-expressed Siglec-5 with NFAT or AP-1 reporters in Jurkat T cells. Our data show
that Siglec-5 strongly inhibits the activity of both NFAT and AP-1 upon activation of the
cells (Figure 9). NFAT and AP-1 are key transcription factors which activity regulates
the expression of genes involved in the activation and effector functions of T cells.
However, we did not provide additional signals that activate the Siglec-5 receptor, which
raises the question how Siglec-5 is activated and how it mediates the inhibitory effects
in this system. Using soluble Siglec-5 receptor we stained and found that Siglec-5 binds
to ~ 20-30% of Jurkat T cells (Figure 19). These data suggest that Jurkat T cells have
putative endogenous ligands that can bind and activate the Siglec-5 receptor.
Most inhibitory receptors with ITIM and ITSM motifs mediate their function
through these domains. We looked at whether in T cells Siglec-5 also mediates its
inhibition via ITIM and ITSM by generating a truncated mutant that lacks these domains.
Interestingly, we observed only a partial restoration of NFAT and AP-1 activity (Figure
10). These data might suggest that ITIM and ITSM domains are only one of the
mechanisms how Siglec-5 mediates its inhibition, and perhaps other domains of Siglec5 are also involved in its functional outcomes. However, we also do not exclude the
possibility that the lack of rescue in NFAT and AP-1 activity (Figure 10) using the
truncated SIglec-5 is just an artifact of the system. Jurkat T cells can express
endogenous Siglec-5 under conditions we don’t yet understand. Since Siglec-5 is a
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dimer, it is possible that pairing of endogenous and truncated Siglec-5 happens and
leads to suboptimal Siglec-5 signaling.
Siglec-5 Follows the Expression Kinetics of Other Checkpoints in T cells
Our data show that Siglec-5 is an inhibitory receptor, and its expression is
strongly dependent on the activation of T cells. This type of kinetics is well described in
the literature for the expression of different checkpoint receptors in T cells. Checkpoint
receptors, including co-stimulatory and co-inhibitory, play a crucial role in regulating the
activation of T cells. Co-stimulatory receptors synergize with TCR signaling and
contribute toward the T cell functional outcome. At peak activation however, opposing,
co-inhibitory receptors begin to be expressed. Co-inhibitory receptors antagonize TCR
signaling and prevent exuberant activation of T cells. Signaling through inhibitory
receptors is a mechanism for mediating tolerance and modulation of the length of T cell
effector function to minimize the collateral damage in the surrounding tissues. The
opposing forces coming from the different checkpoint receptors, co-stimulatory and coinhibitory, which activation depends on their ligand availability, define the fate of T cells
in terms of activation, differentiation, and proliferation. When we compared Siglec-5
expression to other checkpoints we observed an overlap with PD-1 and OX40. Other
checkpoints, such as CTLA-4, 41BB, and ICOS, are expressed by T cells sooner than
Siglec-5, but still share a similar peak expression and downregulation (Figures 6 and 7).
Altogether, our data on the expression kinetics similarity with other checkpoints,
supported with the inhibitory function that it plays in T cells, suggesting that Siglec-5 is a
previously unrecognized inhibitory checkpoint receptor in T cells.
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So why do T cells express multiple different checkpoint receptors upon
activation? One explanation is that the ligands for these receptors are expressed at
different spaciotemporal points and dictate which receptor will be activated.
Furthermore, each checkpoint receptor has a distinct signaling cascade that targets a
specific pathway following T cell activation. In this way, different checkpoint receptors
can augment or suppress specific arms of the T cell effector functions. Finally, it is
possible that T cells need so many checkpoint receptors to successfully lower the
threshold for activation in response to low affinity or low abundance antigens or
decrease the activation state in response to strong stimuli.
Siglec-5 Receptor Activation Using Specific Ligands Suppresses the Activation of
Primary T cells
The overexpression system we used to test the functionality of Siglec-5
confirmed our hypothesis that SIglec-5 is a negative regulator of T cell activation. To
test whether this holds true in primary T cells expressing the endogenous receptor, we
developed a system to activate Siglec-5 using a previously described ligand, -protein.
-protein is a membrane protein and a virulence factor expressed by certain serotypes
of the Group B Streptococcus (GBS) bacteria. This protein encodes several distinct
domains, each capable of inhibiting different arms of the immune system, such as
neutralization of IgA antibodies, inactivation of the complement system and activation of
the inhibitory Siglec-5 receptor. Altogether, -protein mediates immune evasion and
persistence of GBS in the host380. We cloned the most N-terminal region of the protein, B6N (aa1-152), previously described as the domain engaging and activating the
Siglec-5 receptor380. We conjugated the B6N domain to GFP, and then expressed GFP
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as a control. Using ELISA, we verified that the recombinant B6N::sfGFP protein, but not
control sfGFP, binds to Siglec-5 (Figure 11). To test our hypothesis that direct activation
of Siglec-5 antagonizes T cell activation, we used naïve CD4 or CD8 T cells, previously
activated in vitro for 3 days using plate-bound anti-CD3 and anti-CD28. We used this
time point to set up re-stimulation of the T cells because at day 3 all T cells express high
levels of Siglec-5 (Figure 2). Re-stimulation of CD4 T cells, along with activation of
Siglec-5 led to suppressed production of proinflammatory cytokines, IFN- and IL22
(Figure 12A), but an increase in Th2 cytokines, such as IL-4, IL-5, and IL-13 (Figure
12B). Similarly, we also observed reduced IFN- production from CD8 T cells restimulated in the presence of the of Siglec-5 activating signal. IFN- plays a crucial role
in the clearance of GBS in neonates. CD4 depletion during GBS infection decreases the
levels of IFN- produced and leads to an increase in the mortality of infected neonatal
animals381–383. These data stress the importance of CD4-mediated IFN- production.
Our data support the reported observations and provides a potential mechanism for how
GBS can evade the adaptive immune response by activating Siglec-5 signaling and
suppressing cytokine production. The increase in Th2 cytokines produced by CD4 T
cells that we observed in this experimental set up could be justified with two potential
explanations. One is that Siglec-5 signaling directly affects the differentiation, or
maintenance of Th2 cells. To test this hypothesis, we would perform stimulation of naïve
CD4 T cells under Th2 polarizing conditions in the presence of signals that also activate
Siglec-5. If Siglec-5 signaling directly contributes towards Th2 differentiation, we expect
to see increased frequency of Th2 cells. A second explanation is that the increase in
Th2 cytokines is simply due to the reduced production of IFN-. IFN- and IL-4 mediate
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antagonizing physiological responses against each other. IFN- expression is triggered
by APCs-derived IL-12 which can only signal into activated T cells. IL-12 signaling in T
cells leads to more IFN- production. IFN- creates a positive feedback loop that
markedly increases both IFN by T cells and IL-12 by APCs. Furthermore, IFN- also
triggers the expression of the key transcription factor for the Th1 lineage, Tbet. Tbet
itself activates more IFN- production and IL12 receptor expression, but importantly
directly restricts the polarization of T cells into the Th2 lineage75,384,385. Similarly, IL-4,
the key Th2 cytokine is responsible for induction of GATA3 expression, a transcription
factor responsible for the development of the Th2 lineage. Together with GATA3, IL-4
silences the expression of IFN- in T cells, and counters the activity of Tbet76,77. It is
possible that in our system, Siglec-5 targets and suppresses the production of IFN- in T
cells. Subsequently, the production of Th2 cytokines increases due to reduced IFN-
levels that can counter Th2 cytokine production. Alternatively, the decrease in IFN and
increase in Th2 cytokines might be coming from changes in TCR signaling strength in
response to Siglec 5 signaling. Siglec-5 mediates its effects by recruiting Shp
phosphatases to phosphorylated tyrosine residues within the ITIM and ITSM of its
cytoplasmic tail. Engagement of Siglec-5 could lead to de-phosphorylating vital proteins
involved in the TCR signaling cascade, thus decreasing TCR mediated stimulatory
signals. While development of Th1 and Th2 lineages is driven primarily by the specific
cytokines, the strength of the TCR signal in response to antigen plays a role too.
Antigens that bind to TCR with high affinity or are present in abundance induce strong
TCR signaling cascades and trigger the differentiation of Th1 cells. In contrast, antigens
with weak affinity for TCR or low abundance trigger Th2 cell differentiation 386,387. By
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decreasing the strength of the TCR signaling, Siglec-5 might be favoring the production
of Th2 cytokines over the Th1 cytokine IFN-.
Furthermore, in the presence of the -protein signal that activates Siglec-5, CD4
T cells have reduced expression of Granzyme B. Granzyme B is a serine protease most
widely known for its lytic activity towards target cells. Both CD4 and CD8 T cells
produce Granzyme B in response to altered or infected cells. Besides its role in
mediating cell killing, Granzyme B also plays other, intrinsic roles in CD4 T cells, such
as controlling activation-induced cell death of specific subsets. Suppression or
deficiency of Granzyme B production for example, reduces Th2 cell death and
increases animals’ susceptibility to allergen-induced asthma388. Furthermore, one study
reported that Granzyme B is also involved in the differentiation of CD4 T cells, with
Granzyme B sufficient Th1 cells producing more IFN, compared to Granzyme B
deficient ones389. Considering this information, we could speculate that Siglec-5 targets
Granzyme B production in CD4 T cells, and its reduced expression might play a role in
the lowered levels of IFN- produced. Furthermore, lower Granzyme B could also be
allowing for increased survival of Th2 cells, responsible for the increase in Th2
cytokines that we also observe. Upon recognition of infected cells, killer cells deliver
cytotoxic granules containing granzymes to induce apoptosis. Not only do granzymes
target the infected host cell, but also the intracellular bacteria. Through degrading
critical proteins in their electron transport chain complex, Granzymes increase the
oxidative stress by generating reactive oxygen species that kill the bacteria390. However,
Granzyme B released from immune cells can trigger a multistep cell death program in
both intracellular and extracellular pathogens. By cleaving a conserved set of proteins
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among many bacteria, Granzyme B can directly disrupt key biosynthetic and metabolic
pathways that are vital for bacterial survival 391. Since GBS expresses the ligand for
activating the Siglec-5 receptor, we can hypothesize that during an infection with this
pathogen, T cells are less likely to directly kill both infected host cells, but also GBS
itself in a Granzyme B dependent manner. Granzyme B production by CD8 T cells did
not reach statistically significant reduction by Siglec-5 receptor engagement. Proinflammatory effector functions in CD4 T cells are regulated by the transcription factor
Tbet, as T cells deficient for Tbet are defective in their ability to make IFN-. In contrast,
in CD8 T cells T-bet deficient cells still exhibit normal IFN production and cytolytic
activity. T-bet independent CD8 T cells functionality is due to the complementary
functions of another transcription factor, Eomes392,393. Based on the slightly different
response we get from CD4 and CD8 T cell-mediated Granzyme B production upon
engagement of the Siglec-5 receptor, we can hypothesize that Siglec-5 signaling affects
and reduces Tbet expression or function. In such a scenario, the reduction of Tbet
affects CD4 T cell production of Granzyme B because Tbet is the master regulator of
the effector functions. However, in CD8 T cells, reduced Tbet expression/function
doesn’t influence Granzyme B production as much, because of Eomes, which
compensates for the lack of Tbet. To test this hypothesis, we would need to look directly
into the expression and/or function of Tbet in T cells stimulated in the presence of
Siglec-5 activating signals.
We confirmed that B6N mediates its inhibitory effects via Siglec-5 by performing
an assay where B6N was pre-incubated with soluble Siglec-5 Fc protein before coating
the pre-incubated mix on the plate. This way, the B6N is not available for binding by the
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endogenous Siglec-5 receptor once the T cells are added. Using this system, we
observed that we could restore the B6N mediated suppression of Granzyme B
production in CD4 T cells (Figure 18). These data suggest that direct activation of
Siglec-5 antagonizes the activation of T cells and subsequent effector functions.
Altogether, our data from studying T cell effector functions in the presence of
GBS-derived signals that activate the Siglec-5 receptor allow us to propose a model
where GBS can use different mechanisms to not only prevent activation of the innate
immune response as described previously, but also the adaptive immune response. We
propose that during infection, GBS drives suboptimal activation resulting in reduced
production of IFN- as well as reduced expression of Granzyme B by CD4 and CD8 T
cells. By reducing the levels of IFN- produced, GBS not only decreases the proinflammatory responses that IFN- itself promotes, but also the anti-microbial effects
that IFN- can stimulate in antigen-presenting cells394. Furthermore, by suppressing
Granzyme B production, GBS could decrease targeted killing of infected cells or
extracellular bacteria. Reduction in Granzyme B can potentially directly affect the
differentiation of IFN- producing T cells as well. By exploiting the inhibitory functions of
Siglec-5, GBS can successfully evade the T cell-specific immune response and reduce
the overall bacterial clearance (Figure 30). Using this knowledge, we can suggest that
immune therapies targeting Siglec-5 and preventing its activation could be beneficial for
the treatment of GBS. Checkpoint immune therapies for the treatment of infectious
diseases are currently a topic of investigation, as checkpoint-mediated inhibition of T
cell activation can contribute significantly to the pathogenesis of infectious agents. Such
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therapies would be to reverse and improve the functional state of exhausted T cells
during chronic infections such as HIV, malaria, and hepatitis B virus 395.

A)

B)
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Figure 30: GBS Serotypes That Express -protein Suppress the Adaptive Immune
Response and Decrease Overall Bacterial Clearance. A) GBS serotypes that don’t
express the -protein virulence factor are cleared by the robust innate and adaptive
immune response in response to the pathogen B) GBS serotypes that express the protein virulence factor suppress the immune response by activating Siglec-5 in T cells
thus decreasing their IFN- and Granzyme B production leading to decreased IFN
mediated anti-microbial responses coming from APCs as well as decreased Granzyme
B killing of both bacteria and bacteria-infected APCs.
Siglec-5 Signaling Axis is a Mechanism by which Cancers Suppress the Antitumor T cell Response
To escape detection by the immune system, cancers adopt mechanisms for
evasion. One such mechanism is alteration and increase in glycosylated proteins and
lipids, with the addition of sialic acid glycan moieties being one of the most common
modifications. Altered glycosylation can increased the branching of N-glycan structures,
which affects cell-cell adhesions and allows cancer cells to dissociate and metastasize.
Changes in glycosylation of growth factor receptors can alter their signal transduction
pathways and result in modulated cancer cell growth. Increased glycosylation can also
cloak the growing tumor, preventing the recognition of tumor specific-antigens and
subsequent targeted immune response396,397. Finally, cancers can alter their
glycosylation pattern in a way to engage different receptors from the lectin family which
regulate the inflammatory and immune response against the cancers. Tumor-derived
sialic acids are well described to engage Siglec receptors on innate immune cells in the
tumor microenvironment. For example, the activation of Siglec-7 and Siglec-9 suppress
the inflammatory response in monocytes and macrophages while increasing the
expression of immune suppressive cytokines, such as IL-10398. Altogether, altered
glycosylation, and sialyation in particular, play an essential role in mediating

117
suppression of the immune response and thus evasion of cancer recognition and
elimination.
Our data suggest that Siglec-5 is a negative regulator of T cell activation.
Knowing from the literature that sialic acids, the ligands of Siglecs, are often
upregulated and used by cancers to evade the immune response, we asked if the
SIglec-5 signaling axis plays a role in cancer evasion. We stained cancer cell lines from
different tissues using a soluble Siglec-5 receptor and found that Siglec-5 can bind to
varying degrees (Figure 19). While we don’t know what precisely soluble Siglec-5 is
binding to, these data suggest that cancer cell lines express putative ligands that can
bind and activate Siglec-5. Our observations show that cancer cell lines have distinct
subpopulations that Siglec-5 can or cannot bind to. In data not shown, we observed that
the degree of binding of Siglec-5 to the cancer cells depends on the confluency of the
cells. This observation could suggest that Siglec-5 binding depends on different
metabolic, cell cycle, or stress-related states of the cells. Even though Sialic acids are
the main described ligands for Siglec-5, protein ligands such as -protein do exist.
Further studies are needed to evaluate what Siglec-5 is binding to on the different
cancer cells. We hypothesized that disrupting the Siglec-5 receptor/putative ligands
interaction with cancer cells could re-invigorate the anti-tumor T cell response. One of
the cancer cell lines with the highest levels of Siglec-5 binding was the melanoma cell
line MEL624. To test our hypothesis, we used engineered melanoma-specific T cells.
These cells are transduced with a T cell receptor specific for the tyrosinase tumor
antigen and can be activated in an antigen-specific manner. If cancer cells use Siglec-5
to suppress the T cell response, then blocking the ligand availability, using soluble
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Siglec-5-Fc chimeric protein, will reinvigorate the T cells’ effector functions, such as
cytotoxic granule release and cytokine production. We found that in a dose dependent
manner, blocking Siglec-5 putative ligand availability on cancer cells leads to increased
frequency of CD4 T cells producing IL-2, IFN- and TNF-. Cytokine production by
tumor-specific cells is an essential arm of the anti-tumor T cell response, as it
represents the effector functions of the T cells that eventually lead to the killing and
regression of the tumors. IFN-, for example, is a pleiotropic cytokine that overall
coordinates immune surveillance and establishes an effective adaptive immune
response. By enhancing antigen presentation, through upregulating MHC molecule
expression, and the whole antigen processing and presentation machinery399,400, IFN-
initiates antigen exposure and subsequent triggering of a targeted immune response.
As the major cytokine produced by pro-inflammatory Th1 T cells and cytotoxic CD8 T
cells, IFN- not only orchestrates the effector response but also contributes to the
maintenance and differentiation of these cells. Finally, IFN- can directly induce tumor
cell killing through the activation of various mechanisms such NADPH-dependent cell
killing, production of NO, depletion of tryptophan, as well as upregulation of lysosomal
enzymes401. The role of TNF in cancer is controversial, with some studies reporting
anti- and others pro-tumorigenic effects. TNF can be produced by cancer cells to
promote their growth, metastasis, and angiogenesis. However, TNF produced by T
cells contributes to cancer cell death, both directly, but also through the activation of
cytotoxic programs in other immune cells. It has been reported that TNF plays an
essential role during priming, proliferation, and recruitment of T cells to the cancer site.
Furthermore, this necessity is only true under suboptimal T cell activation conditions, as
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is cancer, where co-stimulation and cytokines are limited402. IL-2 is the critical cytokine
required for the growth of T cells403. IL-2 is predominantly secreted by CD4 T cells, but
CD8, NK and dendritic cells can also produce some levels too 404,405. Not only is IL-2
essential for the survival and growth of T cells, but also for the differentiation of naïve
CD4 T cells into different subsets406–408, enhancement of the cytotoxic program in CD8
T cells409, and the suppressive functions of regulatory T cells408,410. Because of its
importance in sustaining T cell survival as well as functionality, IL-2 has been a
candidate for cancer immunotherapy since its discovery in 1976, and first received FDA
approval for treatments in 1992. Nowadays, IL-2 is used in monotherapies, or in
combination with other therapies such as chemo, immune checkpoint blockade and
adoptive cell transfer. Besides cytokines, we also see increased frequency of cells
expressing CD107a, a marker for cytotoxic degranulation. CD107a, also known as
LAMP-1, is a lysosome-associated molecule that marks cells that have released
cytotoxic granules (CGs). CGs are specialized lysosomes that comprise of granzymes
and perforins. Perforins can bind target cells and create membrane holes through which
granzymes can be delivered into the cytoplasm where they induce cell apoptosis 411–413.
Altogether, the increased frequency of cytokine-producing cells, as well as cells
that have undergone cytotoxic granule release suggest that blocking the Siglec-5
signaling axis reinvigorates the effector functions of tumor-specific cells. Based on these
in vitro results, we hypothesize that in vivo, countering the activation of Siglec-5 would
enhance the T cell response against the cancer. The increased production of IL-2 will
support the growth, differentiation, and maintenance of the tumor-specific T cells. The
increased IFN- and TNF- production will lead to enhanced direct killing of the cancer
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cells, as well as increased recruitment and functionality of the T cells, followed by
increased antigen presentation and targeted cancer cell killing by cytotoxic granule
release. We did not measure direct tumor cell killing; however, based on the increased
cytokine production and granule release, we hypothesize that cytolysis is increased as
well (Figure 31).
In the assay system used here, T cells are initially stimulated under optimal
conditions. We used the APC-like cell line T2 pulsed with tyrosinase to activate and
induce Siglec-5 expression, before re-stimulating the cells with the cancer cell line
MEL624 to measure the effects of disrupting the Siglec-5 signaling axis. Cancer cells
often drive the development of anergic T cells, which don’t produce cytokines with
maximum capacity. In cancer, anergic T cells result from repeated antigen stimulation or
stimulation under suboptimal conditions where co-stimulatory signals are lacking. We
hypothesize that this is the reason why CD8 T cells do not produce any cytokines during
the restimulation with the cancer cell lines. However, the assay system of re-stimulation
mimics the repeated stimulation of T cells in the tumor microenvironment, and the
reinvigoration of CD4 T cell functionality with blocking of Siglec-5 signaling could have a
great therapeutic implication.
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A)

B)

Figure 31: Siglec-5 Signaling Axis is a Mechanism by which Cancers Evade the T
cell-specific Immune Response. A) Cancers increase their surface sialyation and, in
that way, can engage the Siglec-5 receptor expressed on activated T cells.
Subsequently, Siglec-5 dampens the anti-tumor T cell response, allowing for cancers to
progress. B) Blocking ligand availability using soluble Siglec-5 receptor disrupts the
Siglec-5 signaling axis and reinvigorates the T cell response to cancers.
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Siglec-5 as a Target for Cancer Immune Checkpoint Therapy Development
Checkpoint receptors have become a major target for designing cancer
immunotherapies. Immune checkpoint blockade therapies work by releasing the breaks
and allowing T cells to mount a robust immune response. To date, across 14 different
malignancies, the FDA has approved 7 different drugs, targeting 3 different inhibitory
checkpoints, namely PD-1, PD-L1 and CTLA-4. The approval of these therapies has
revolutionized the way malignancies are treated nowadays and has brought hope and
commodity for many patients. However, based on a 2018 study, even though ~43.6 %
of cancer patients in the US are predicted to respond to immune checkpoint therapies,
the percentage of patients that respond is ~ 12.5%414. This low response rate is due to
either primary or acquired resistance and suggests that blocking one inhibitory pathway
is not enough to rescue the T cell response, as compensatory mechanisms by other
checkpoint receptors are upregulated to prevent T cell activation. As a result, extensive
research has been focusing on identifying new checkpoint receptors. Currently,
emerging immune checkpoint targets such as lymphocyte activation gene-3 (LAG-3)415,
T cell immunoglobulin and ITIM domain (TIGIT)416, T cell immunoglobulin and mucindomain containing-3 (TIM-3)417, V-domain Ig suppressor of T cell activation (VISTA)418,
B and T cell lymphocyte attenuator (BTLA)419 and B7 homolog 3 protein (B7-H3)420 are
all under investigation in pre-clinical or clinical trials. Our data show that Siglec-5 is a
previously unidentified checkpoint receptor, that mediates strong inhibitory effects
leading to suppressed T cell responses against tumor cells, similarly to all other
inhibitory checkpoints described to date. The identification of yet another checkpoint is
of great importance as it can serve as a target for the development of novel checkpoint
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inhibitor therapies. From our work we see that the single agent blockade of Siglec-5
strongly reinvigorates the T cell response. Alone, or in combination with other
checkpoint targets, blockade of Siglec-5 can serve as a strategy to prevent cancer
immune evasion.
Siglec-5 as a Target for Immune Therapies to Treat Autoimmune Disorders
Cancer and autoimmunity are on the opposite sides of the balance that maintains
immunological homeostasis. In cancer, the immune response is suppressed and
therapies such as checkpoint inhibitors work well to restore the immune response.
However, a major side effect of checkpoint inhibitor therapies for cancer is the
appearance of immune-related adverse events (IRAEs), which manifest as autoimmune
phenotypes in a wide range of organs such as the skin, gut, lungs, kidneys, pancreas,
or hematopoietic system421. Furthermore, genetic ablation of checkpoint receptors in
laboratory animals215,216,226,227, along with rare cases of human deficiencies422, result in
severe autoimmune disorders in multiple organs. These studies stress the importance
of checkpoint receptors in maintaining immunological tolerance and raise the possibility
of targeting and blocking their activity as potential treatments for autoimmunity. The goal
of such therapies would be to target and increase their inhibitory activity to suppress
overreactive immune responses. Attempts to use checkpoints receptors as a target for
autoimmune therapies are already underway, with efforts to develop agonists agents or
antibodies that enhance the inhibitory signaling of checkpoint receptors such as PD-1,
BTLA, TIGIT, TIM3423. Identifying Siglec-5 as a novel inhibitory checkpoint receptor
adds another potential target for autoimmunity therapy development. Based on our data
showing the strong suppression that Siglec-5 activation can mediate, we hypothesize
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that in auto reactive T cells this could be beneficial and would serve to dampen the
inflammation and effector functions targeted against self-antigens. Combination
therapies are superior to single agent in cancer treatments, and we can predict that
targeting multiple inhibitory pathways in autoimmunity may be more efficient in
mediating immunosuppression. Identifying new checkpoint receptors for the design of
immune therapies is of great importance as it would allow for the careful design of
therapies that combine different targets, with or without redundant signaling pathways,
and would help to really unravel the true potential that this class of therapeutics have.
Section II
Development of Novel Tools to Identify TGF-β Producing Cells
Transforming growth factor β (TGF-β) is a pleiotropic cytokine involved in
regulating of many cellular processes372. Initially secreted as a part of an inactive
complex with the latency-associated protein (LAP), TGF-β signaling is initiated only
upon release of active TGF-β from the inhibitory complex424. However, even though the
biological functions of TGF-β are well established, where, when, or how latent TGF-β is
activated is not well understood. Several studies suggest that active TGF-β is
expressed on cell surfaces329,339. Although several anti-TGF-β antibodies are
commercially available, detecting cell-surface bound active TGF-β remains challenging
and is not well documented. The most widely used 1D11 antibody clone serves well for
neutralizing TGF-β, but not for immunofluorescent detection purposes. This technical
hurdle leaves a knowledge gap in the TGF-β field.
Using phage display technology, we generated a reagent that binds active but
not latent TGF-β. We chose phage clone 6 (Ph6) for further analysis and
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characterization because of its superior affinity for active TGF-β compared to the other
clones (Figure 23A). We also confirmed that not only does Ph6 bind to TGF-β, but it
also neutralizes TGF-β’s physiological functions, such as phosphorylation of SMAD2/3
proteins, as well as the induction of epithelial to mesenchymal transition (Figure 23B
and 23C). From our previous studies we knew that human CD14+ monocytes require
cell-cell contact to induce TGF-β mediated differentiation of naïve T cells into regulatory
T cells375. Using fluorescently labeled Ph6 we stained and found that Ph6 binds to
human CD14+ monocytes, suggesting that these cells express active TGF-β on their
surface. Human CD14+ monocytes have been reported to activate high levels of TGF-β
as a mechanism to dampen inflammation. Mechanistically, these cells use the integrin
V8 to mediate the activation of TGF-β. The integrin expression and the ability to
activate TGF-β is still maintained even when monocytes differentiate into macrophages.
This type of macrophage plays a vital role in maintaining tolerance in the gut. During
active inflammatory bowel disease, the frequency of these macrophages and the levels
of integrin V8 are significantly decreased, stressing their importance during
inflammatory responses and the maintenance of intestinal homeostasis 425. Studies from
our lab and others show that CD14+ monocytes also express Thrombospondin 1 (TSP),
another well characterized cofactor involved in the conversion of latent to active TGF-β
327,375.

Altogether, our lab and others have documented that CD14+ monocytes mediate

TGF-β specific functions leading to tolerance and tissue homeostasis. But, for the first
time we report that CD14+ monocytes can perform such functions by activating and
directly presenting active TGF-β to the target cells in the environment. However, active
TGF-β does not have a membrane anchoring region, and its presence on the cell
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surface would suggest that unidentified mechanisms enable cells to retain active TGF-β
on the cell surface. Our method of detection of surface-bound active TGF-β can serve
as a tool to study how TGF-β is retained on the cell surface, what other molecules it
associates with on the surface, and how it interacts with other cells using biochemical or
immunofluorescent methods.
We sought then to generate a recombinant protein expressing the fibronectin
type III domain, FN3, (i.e., ligand-binding domain) of Ph6. Previously, our lab had tried
to generate recombinant proteins containing just the FN3 domain of Ph6. However,
those experiments were unsuccessful, and no soluble proteins were recovered (data not
shown). Instead, we generated a FN3-hIgG1 Fc chimeric protein that contains the FN3
sequence of Ph6 conjugated to the Fc region of hIgG1 (6FN3-Fc). As a control we used
the wild-type FN3 domain (WTFN3-Fc). The FN3 and Fc domains were spaced with the
hinge region of hIgG1, which allows for flexibility and dimerization of the expressed
proteins. We successfully expressed the FN3-hIgG1 Fc chimeric proteins using a
eucaryotic expression system and verified their ability to bind active TGF-β via ELISA.
However, the proteins were not suitable for staining purposes, as we did not detect any
binding to human CD14+ monocytes, like we saw with the Ph6. We tried several
different detection methods for Clone 6 FN3-hIgG1 Fc binding to CD14+ monocytes: 1)
Fluorochrome conjugated anti-human IgG Fc; 2) direct conjugation of Alexa
Fluorochromes to clone 6 FN3-hIgG1 Fc; 3) biotinylating of clone 6 FN3-hIgG1 Fc and
found that in all cases the recombinant protein can bind active TGF-β by ELISA, but not
active TGF-β on cell surfaces. One thing to remember about the phage platform is that
the FN3 domain is expressed as a fusion of the minor coat protein III, which has at least
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4-5 copies expressed per phage particle, in contrast to the two binding sites in our
recombinant protein. Thus, it is possible that in comparison to the recombinant protein,
the phage particles have higher avidity and can detect active TGF-β on CD14+
monocytes. In the future, we will try to optimize the labeling, as well as staining
conditions using the recombinant proteins.
Potential for Diagnostics and Therapeutic Tool Development
By having a reliable reagent that binds and detects active TGF-β specifically, we
can start asking basic science questions about where and how is latent TGF-β
converted into the active form. Furthermore, we can also use this reagent as a
diagnostic tool intended to identify cells and tissues that express active TGF-β and
predict how those cells regulate tissue homeostasis. In addition, numerous studies have
reported the role of TGF-β in promoting tumor growth. Having a tool that can help us
evaluate the presence of TGF-β in different cancers can help design targeted strategies
to overcome TGF-β pro-tumorigenic functions.
Besides using it as a diagnostic tool, Ph6 also has the potential for therapeutic
development. It is well established that cancer progression relies on avoiding immune
surveillance and developing an immunosuppressive environment that hinders the antitumor immune response. One aspect of TGF- β mediated cancer immune evasion is the
restriction of differentiation and activation of anti-tumor T cells. Single-agent inhibition of
TGF-β in cancer treatment has yielded inconsistent results with limited clinical
significance, and combination therapies may be a better approach to harness TGF-β
immunosuppression. One such approach to enhance the anti-tumor response is
engineering tumor specific T cells that are also insensitive to TGF-β suppression. Based
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on our results showing that Ph6 neutralizes TGF-β physiological functions, we can
hypothesize that engineering T cells that express clone 6 FN3 as a decoy receptor,
along with a tumor-specific TCR, will enhance the anti-tumor effect of the engineered T
cells in the presence of TGF-β. The development of cells resistant to TGF-β would be
neccessary for its clinical significance as we can design combination immune therapies
that can improve the survival of cancer patients. Furthermore, it will also be important
from a fundamental science standpoint because it can allow us to study how T cells
behave in the absence of TGF-β.
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